Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.35 - tissue kallikrein and Organism(s) Homo sapiens and UniProt Accession Q9UBX7

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion.
Acquired Immunodeficiency Syndrome
The potential contribution of decision aids to screening programmes.
[Significance of the PSA-concentration for the detection of prostate cancer]
Acute Coronary Syndrome
Editorial Comment on: Is There a Relationship Between Acute Coronary Syndrome and Prostate Specific Antigen Level?
Is there a relationship between acute coronary syndrome and prostate specific antigen level?
Acute Kidney Injury
Evidence for intrarenal kallikrein storage during chromate-induced acute renal failure in rat.
Renal kallikrein excretion and epigenetics in human acute kidney injury: Expression, mechanisms and consequences.
Adenocarcinoma
A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature.
A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy.
A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate.
A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia.
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Adenocarcinoma of urinary bladder: A report of two patients.
Anejaculation as an atypical presentation of prostate cancer: a case report.
Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels.
Bullous pemphigoid associated with prostate adenocarcinoma.
Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature.
Carcinosarcoma of the prostate. Report of 21 cases.
Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas.
Challenges in diagnosis and treatment of a cervical spinal cord injury patient with melanoma, adenocarcinoma, and hepatic and osteolytic metastases: need to implement strategies for prevention and early detection of cancer in spinal cord injury patients.
Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL.
Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
Collet-Sicard syndrome: a rare presentation of metastatic prostate adenocarcinoma.
Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
Diagnosis and Conservative Management of Ureteral Orifice Injury During Robotic Prostatectomy for a Large Prostate with a Prominent Median Lobe.
Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.
DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 prostate cancers.
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen.
Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: A pilot study.
Early outcomes of active surveillance for localized prostate cancer.
Eosinophilic pneumonia and thoracic metastases as an initial manifestation of prostatic carcinoma.
Female para-urethral adenocarcinoma: histological and immunohistochemical study.
Gleason Score Correlation Between Prostate Needle Biopsy and Radical Prostatectomy Materials.
Histopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue.
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Hydronephrosis associated with ureteral metastasis of prostate cancer: A rare case report.
Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues.
Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions.
Incorrect biochemistry complicates prostate cancer management.
Interstitial microwave thermal therapy for prostate cancer: method of treatment and results of a phase I/II trial.
Invasive carcinoma of prostate presenting as rectal carcinoma.
Is high grade prostatic intraepithelial neoplasia still a risk factor for adenocarcinoma in the era of extended biopsy sampling?
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Laparoscopic repair of external iliac-artery transection during laparoscopic radical prostatectomy.
Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate.
Malignant anterior urethral strictures: a rare complication of transurethral resection of malignant prostate.
Metastasis of Occult Prostatic Carcinoma to the Sphenoid Sinus: Report of a Rare Case and a Review of the Literature.
Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level.
Metastatic prostatic adenocarcinoma with neuroendocrine differentiation to meningioma.
MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma.
Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID.
Mycosis fungoides in plaque stage with pronounced eosinophilic infiltration, folliculotropism, and concomitant invasive squamous cell carcinoma.
Neoadjuvant Hormonal Therapy in Stage C Adenocarcinoma of the Prostate and Incidence of Biochemical Recurrence.
New cancer markers.
Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
Outcome based staging for clinically localized adenocarcinoma of the prostate.
Paget's disease primarily involving the scrotum.
Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy.
Periprostatic subendothelial intravascular granulomatosis: a mimic of high-grade intravascular prostatic adenocarcinoma.
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Predictive value of PSA velocity over early clinical and pathological parameters in patients with localized prostate cancer who undergo radical retropubic prostatectomy.
Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.
Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Prostate Cancer Presenting as Huge Mediastinal and Retroperitoneal Masses: Case Report and Review of the Literature.
Prostate carcinoma with squamous differentiation: an analysis of 33 cases.
Prostate specific antigen after irradiation for prostatic carcinoma.
Prostate specific antigen and prostate specific acid phosphatase in adenocarcinoma of Skene's paraurethral glands and ducts.
Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Prostatic ductal adenocarcinoma showing Bcl-2 expression.
Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.
Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.
Re: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels.
Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate.
Re: Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)
Rectal Hem-o-Lok clip migration after robot-assisted laparoscopic radical prostatectomy.
Recurrent prostate cancer despite undetectable prostate specific antigen.
Review article Salvage surgery for locally recurrent prostate cancer after radiation therapy.
Serum prostate specific antigen levels are not elevated in most of the patients with advanced pancreatic adenocarcinoma.
Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy.
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
The impact of prostatic manipulation upon serum PSA in patients with adenocarcinoma of the prostate.
The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.
The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
The use of RT-"nested" PCR of prostate specific antigen to detect hematogenous neoplastic cells in patients with prostate adenocarcinoma.
Unusual metastatic patterns of prostate adenocarcinoma.
Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma.
Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values.
Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy.
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
[A case of brain metastasis associated with prostate cancer]
[A case of clear cell adenocarcinoma of the female urethra]
[A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy].
[A Case of Neuroendcrine Carcinoma of the Prostate Diagnosed by Prostate Re-Biopsy during Hormonal Treatment and Effectively Treated by Multidisciplinary Therapy].
[A case of prostate cancer with invasion to the middle ureter]
[A case of prostatic ductal adenocarcinoma with endometrioid features, associated with rectal invasion and multiple liver metastases]
[A Case of Rapidly Progressive Metastatic Castration-Resistant Prostate Cancer : Durable Control by Early Induction of Carboplatin and Paclitaxel].
[An immunohistological study of metastatic adenocarcinoma of the lymph node: is it useful in diagnosing a primary tumor?]
[Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels]
[Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report].
[Preliminary data on our laparoscopy experience in urinary pathology]
[Primary adenocarcinoma of the male urethra].
[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]
[Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements]
[Signet ring cell carcinoma of the prostate successfully treated with endocrine therapy: a case report]
[Small cell carcinoma of the prostate: a case report]
[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]
Adenocarcinoma of Lung
Expression of the prostate specific antigen gene by lung tissue.
Adenocarcinoma, Clear Cell
[A case of clear cell adenocarcinoma of the female urethra]
Adenocarcinoma, Mucinous
[Mucinous adenocarcinoma of the prostate: a case report and review of 32 cases on immunohistochemical study of both PSA and CEA]
[Two cases of mucinous adenocarcinoma of the prostate]
Adenocarcinoma, Papillary
[A case of ductal adenocarcinoma of prostate associated with retroperitoneal multiple cysts].
Adenoma
A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection?
Characterization of a tissue kallikrein in human prolactin-secreting adenomas.
Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma.
Regional distribution of tissue kallikrein in the human brain.
Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
Adenoma, Villous
Villous adenoma of the urachus: a case with prostate specific antigen immunoreactivity.
Aggressive Periodontitis
[Role of salivary kallikrein in the pathogenesis of periodontosis]
Alkalosis
Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion.
Alopecia
Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
Alveolitis, Extrinsic Allergic
Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice.
Alzheimer Disease
A top 5 list for French general practice.
Increased free prostate specific antigen serum levels in Alzheimer's disease, correlation with Cognitive Decline.
Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Regional distribution of tissue kallikrein in the human brain.
The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons.
Anemia
Laboratory evaluations of erectile dysfunction: an evidence based approach.
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Anemia, Sickle Cell
Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease.
Aneurysm
Serine proteases and cardiac function.
Aortic Aneurysm, Abdominal
A single nucleotide polymorphism in exon 3 of the kallikrein 1 gene is associated with large but not small abdominal aortic aneurysm.
Arthritis
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Arthritis, Psoriatic
Determination of tissue kallikrein and alpha 1-antitrypsin-tissue kallikrein complexes in synovial fluid of patients with rheumatoid, osteo and psoriatic arthritis.
Granulomatous prostatitis mimicking prostate cancer in a patient with psoriatic arthritis: a case report.
Arthritis, Rheumatoid
A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis.
Expression and characterization of human tissue kallikrein variants.
Immunocytochemical analysis of tissue kallikrein and the kinin moiety in rheumatoid synovial fluid neutrophils.
Inhibitor regulation of tissue kallikrein activity in the synovial fluid of patients with rheumatoid arthritis.
Kallikreins and kininogens in saliva and plasma of patients presenting with rheumatoid arthritis.
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Presence of immunoreactive tissue kallikrein in human polymorphonuclear (PMN) leucocytes.
Asthma
Bivalent antibody pliers inhibit ?-tryptase by an allosteric mechanism dependent on the IgG hinge.
Bivalent inhibition of human beta-tryptase.
Dual functionality of ?-tryptase protomers as both proteases and cofactors in the active tetramer.
Expression and characterization of human tissue kallikrein variants.
Kinin receptors on epithelial cells and smooth muscle of the trachea.
Leukocytic cell sources of airway tissue kallikrein.
Localization of immunoreactive tissue kallikrein in human trachea.
Localization of immunoreactive tissue kallikrein in the seromucous glands of the human and guinea-pig respiratory tree.
Atherosclerosis
Induction of tissue kallikrein in human carotid atheroma does not lead to kallikrein-kinins pathway activation.
Patient selection and counseling before prostatic arterial embolization.
Autoimmune Diseases
Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome.
Autoimmune Pancreatitis
IgG4-Related Autoimmune Prostatitis: Is It an Unusual or Underdiagnosed Manifestation of IgG4-Related Disease?
Azoospermia
Evaluation of three rapid detection methods for the forensic identification of seminal fluid in rape cases.
Bacterial Infections
Characterization and expression analysis of a trypsin-like serine protease from planarian Dugesia japonica.
Bacteriuria
[Granulomatous Prostatitis : Three Cases Report].
Bartter Syndrome
[The pathophysiological significance of increased renal kallikrein excretion in Bartter's syndrome (author's transl)]
Bone Resorption
The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone.
Brain Infarction
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
Brain Injuries
Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway.
Brain Injuries, Traumatic
Determination of serum tissue kallikrein levels after traumatic brain injury.
Brain Ischemia
Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke.
Experimental therapy with tissue kallikrein against cerebral ischemia.
Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB.
Tissue kallikrein promotes survival and ??catenin degradation in SH?SY5Y cells under nutrient stress conditions via autophagy.
Tissue kallikrein protects SH-SY5Y neuronal cells against oxygen and glucose deprivation-induced injury through bradykinin B2 receptor-dependent regulation of autophagy induction.
Tissue kallikrein: A potential serum biomarker to predict delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage.
Brain Neoplasms
Brain metastasis from prostate small cell carcinoma: not to be neglected.
Breast Cyst
Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid.
Prostate specific antigen in the female body: its role in breast cancer prognosis.
Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease.
Prostate specific antigen--a new constituent of breast cyst fluid.
Prostatic acid phosphatase in breast cyst fluid.
Breast Diseases
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Breast Neoplasms
Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the kinin B? receptor in breast cancer cells.
Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter.
Correlation of prostate specific antigen immunoactivity (IR-PSA) to other prognostic factors in female breast cancer.
Detecting exosomes specifically: a multiplexed device based on alternating current electrohydrodynamic induced nanoshearing.
Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids.
Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines.
Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary.
Effect of cathepsin D and prostate specific antigen on latent transforming growth factor-beta in breast cancer cell lines.
Ethical issues for cancer screening.
Ethical issues for cancer screenings. Five countries--four types of cancer.
Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions.
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D.
Expression of prostate specific antigen in male breast cancer.
Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.
Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing.
IGFs and human cancer: implications regarding the risk of growth hormone therapy.
Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells.
Immunohistochemical analysis of prostate specific antigen in breast cancer.
Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines.
Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis.
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells.
Modeling the overdetection of screen-identified cancers in population-based cancer screening with the Coxian phase-type Markov process.
New cancer markers.
Online, Interactive Option Grid Patient Decision Aids and their Effect on User Preferences.
Oral testosterone replacement in Korean patients with PADAM.
Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
Prevalence of the use of cancer related self-tests by members of the public: a community survey.
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.
Prostate specific antigen as a biomarker for breast cancer: a meta-analysis study.
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Prostate specific antigen in the female body: its role in breast cancer prognosis.
Prostate specific antigen in women with breast cancer: is it amenable to routine immunohistochemical detection?
Prostate specific antigen production by breast tumors after induction with oral contraceptives.
PS3-42: Health Literacy and Cancer Prevention: It's Not What You Say It's What They Hear.
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.
Serum IGF-binding protein-6 and prostate specific antigen in breast cancer.
Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.
Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
Unrealistic optimism and the Health Belief Model.
Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina.
Visualization of tissue kallikrein in human breast carcinoma by two-dimensional western blotting and immunohistochemistry.
Breast Neoplasms, Male
Expression of prostate specific antigen in male breast cancer.
Bronchitis
A top 5 list for French general practice.
[Method for determining kallikrein of tissue origin in blood plasma and its clinical significance]
Carcinoid Tumor
Flushing in the carcinoid syndrome and plasma kallikrein.
Grossly elevated serum prostatic acid phosphatase in a patient with carcinoid.
Prostate-specific acid phosphatase in carcinoid tumors.
Carcinoma
A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.
A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy.
A neurocomputational model for prostate carcinoma detection.
A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells.
A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor.
A novel protease homolog differentially expressed in breast and ovarian cancer.
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.
A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate.
A prospective study of the serum prostate specific antigen concentrations and Gleason histologic scores of black and white men with prostate carcinoma.
Activity of Artemisia annua and artemisinin derivatives, in prostate carcinoma.
Adenocarcinoma of the rete testis with prominent papillary structure and clear neoplastic cells: morphologic and immunohistochemical findings and differential diagnosis.
Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma.
Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
An evaluation of prostate specific antigen in prostatic cancer.
An unusual case of metastatic small intestinal tumor due to prostate cancer.
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Androgen effect on prostate specific antigen secretion.
Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein.
Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review.
Bilateral third and unilateral sixth nerve palsies as early presenting signs of metastatic prostatic carcinoma.
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?
Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Cerebellar metastases from prostatic carcinoma.
Changes in beta-2 microglobulin expression in prostate cancer.
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide.
Chest radiography in patients with early stage prostatic carcinoma. Effect on treatment planning and cost analysis.
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
Clinical use of prostate-specific antigen in the staging of patients with prostatic carcinoma.
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.
Comparative analysis of whole saliva proteomes for the screening of biomarkers for oral lichen planus.
Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.
Comparisons of the incidence and pathological characteristics of prostate cancer between Chinese and Portuguese in Macau.
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African Americans.
Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Current prognostic factors for prostate carcinoma.
Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience.
Dedifferentiated Epithelial-Myoepithelial Carcinoma of the Parotid Gland With Aberrant Expression of Prostate Specific Antigen: A Case Report.
Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.
Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma.
Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.
Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics.
Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum.
Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells.
Eight years of "Prostate Cancer Awareness Week": lessons in screening and early detection. Prostate Cancer Education Council.
Elevated prostate specific antigen (PSA) levels a risk factor for pathological hip fracture in metastatic prostatic carcinoma.
Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?
Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients.
Establishment of human prostate carcinoma skeletal metastasis models.
Evaluation of commercial immunoperoxidase kits in diagnosis of prostate carcinoma.
Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma.
Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.
Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases.
Exploration on Gleason score variation trend of patients with prostate carcinoma from 1996 to 2019: a retrospective single center study.
Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues.
Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate.
Expression of tissue kallikrein in human kidney.
Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.
False positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
Gleason Score Correlation Between Prostate Needle Biopsy and Radical Prostatectomy Materials.
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
Gonadotropin-releasing hormone/human chorionic gonadotropin beta based recombinant antibodies and vaccines.
Hepatocellular carcinoma metastatic to the gingiva as a first manifestation of hepatocellular carcinoma.
High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment.
Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report.
Identification of metastatic disease by T category, gleason score and serum PSA level in patients with carcinoma of the prostate.
Imaging of prostate carcinoma.
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Immunohistologic diagnosis of 2 cases of metastatic prostate cancer to breast.
Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites.
Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma.
Increased expression of protease M in ovarian tumors.
Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.
Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score ?3 + 3 = 6 Upon Schematic TRUS-Guided Biopsy: A Radical Prostatectomy Correlated Series.
INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY.
Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma.
Intraindividual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma.
Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen.
Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy.
Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.
Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma.
Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.
Mechanisms by which Interleukin-6 Regulates Prostate Specific Antigen Gene Expression in Prostate LNCaP Carcinoma Cells.
Metastatic carcinoma of the prostate mimicking primary carcinoid tumor of the lung and mediastinum.
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Migrations in clinical and pathological stage of prostatic carcinoma in patients undergoing radical prostatectomy in the period between 1993 and 2003.
Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma.
Molecular cloning, purification and in situ localization of human colon kallikrein.
Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population.
New cancer markers.
Novel stably transfected human reporter cell line AIZ-AR as a tool for an assessment of human androgen receptor transcriptional activity.
Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma.
Origin of carcinomas causing bladder neck obstruction demonstrated by immunoperoxidase localisation of specific antigens.
Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies.
Paraneoplastic bleeding disorder due to isolated hypofibrinogenemia: A case report.
Pathologic classification of prostate carcinoma: the impact of margin status.
Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score
Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort.
Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels.
Phase II study of CI-958 in patients with hormone refractory prostate carcinoma.
Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Positive correlation of serum parathormone and prostate specific antigen levels in prostate cancer.
Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Predicting the pathology results of radical prostatectomy from preoperative information: a validation study.
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies.
Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.
Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations.
Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
Prostate biopsy in patients after proctectomy.
Prostate Cancer and Its Mimics at Multiparametric Prostate MRI.
Prostate cancer screening in the Tyrol, Austria: experience and results.
Prostate carcinoma knowledge, attitudes, and screening behavior among African-American men in Central Harlem, New York City.
Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen.
Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma.
Prostate specific antigen after irradiation for prostatic carcinoma.
Prostate specific antigen and local recurrence after radical prostatectomy.
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.
Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma.
Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma.
Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy.
Prostate specific antigen density in patients with histologically proven prostate carcinoma.
Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma.
Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate.
Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma.
Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.
Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma.
Prostate specific antigen levels during and after external beam radiotherapy for localized carcinoma of the prostate: predictor of therapeutic efficacy.
Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate.
Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma.
Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma.
Prostatic acid phosphatase in breast cyst fluid.
Prostatic Inflammation Detected in Initial Biopsy Specimens and Urinary Pyuria are Predictors of Negative Repeat Prostate Biopsy.
Pulmonary embolus as a first presentation of occult metastatic prostate cancer.
Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study.
Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma.
Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis.
Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.
Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Re: False-positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Re: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma.
Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma.
Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma.
Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate.
Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Role of colour Doppler imaging in detecting prostate cancer.
Role of digital rectal examination and prostate specific antigen in detecting carcinoma prostate.
Role of screening in detection of clinically localized prostate cancer.
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Screening for cancer. Is it useful?
Screening for carcinoma of the prostate with prostate specific antigen.
Screening for prostatic carcinoma with prostate specific antigen.
Screening for prostatic carcinoma with prostate specific antigen: results of the second year.
Screening for prostatic carcinoma.
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization.
Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate.
Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate.
Serum ceruloplasmin as a marker in prostate cancer.
Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Structure-guided design of peptidic ligand for human prostate specific antigen.
The age of the urologist affects the postoperative care of prostate carcinoma patients.
The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.
The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.
The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma.
The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men.
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.
The effect of prostate volume on the yield of needle biopsy.
The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful!
The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma.
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma.
The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.
The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
The new human tissue kallikrein gene family: structure, function, and association to disease.
The outcome of elevated prostate specific antigen and transrectal ultrasound guided prostatic biopsy in detecting carcinoma of the prostate: initial experience in Sri Lanka.
The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
The presence of atypical small acinar proliferation in prostate needle biopsy is predictive of carcinoma on subsequent biopsy.
The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma.
The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate.
The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.
The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule.
The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view.
The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma.
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.
Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma.
Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate.
Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.
Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.
Unusual Uptake of Prostate Specific Tracer (68)Ga-PSMA-HBED-CC in a Benign Thyroid Nodule.
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy.
Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder.
Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
Utility of Seriated Sections in Prostate Biopsies.
Values of prostate specific antigen in patients with operable prostate carcinoma.
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy.
Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma.
[A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma]
[A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report]
[Adenocarcinoma of the prostate]
[Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival]
[Changes in tumor markers following cryosurgery of prostate carcinoma]
[Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma]
[Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen]
[Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]
[Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma]
[Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]
[Early detection of prostate carcinoma. What diagnosis is of value when?]
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
[Obstructive jaundice in prostate neoplasm. Case report]
[Primary adenocarcinoma of the female urethra treated by multimodal therapy]
[Primary squamous cell carcinoma of the prostate: a case report]
[Prognostic importance of prostate specific antigen in patients with hormonally treated stage D2 prostate carcinoma]
[Proper use of prostate specific antigen]
[Prostate biopsy: assessment of current indications and techniques]
[Prostate specific antigen (PSA) in the diagnosis and treatment of prostate carcinoma: advances and controversies]
[Prostate-specific antigen as a tumor marker of prostate carcinoma]
[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma]
[Prostatic carcinoma. Screening--when and what?]
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
[Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer]
[Serum tumor marker levels during a 12-months growth hormone replacement therapy in patients with adult growth hormone deficiency]
[Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course]
[The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate]
[The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy]
[The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method]
[The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma]
[Ultrasonography of the prostate]
[Value of PSA in the staging of prostatic cancer]
[Will determination of prostate specific antigen density improve the diagnosis of prostatic carcinoma?]
Carcinoma in Situ
Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.
Carcinoma, Bronchogenic
Screening for cancer. Is it useful?
Carcinoma, Ductal
Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.
Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.
Carcinoma, Hepatocellular
A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells.
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
Carcinoma, Intraductal, Noninfiltrating
Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.
The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure.
Carcinoma, Ovarian Epithelial
New cancer markers.
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
Carcinoma, Renal Cell
Adenocarcinoma of the rete testis with prominent papillary structure and clear neoplastic cells: morphologic and immunohistochemical findings and differential diagnosis.
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
False positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Re: False-positive prostate specific antigen values in the sera of women with renal cell carcinoma.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Carcinoma, Small Cell
Changes in beta-2 microglobulin expression in prostate cancer.
New cancer markers.
Carcinoma, Squamous Cell
Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort.
Prostate carcinoma with squamous differentiation: an analysis of 33 cases.
The biosynthesis of prostate-specific antigen in non prostatic cell lines.
[Primary adenocarcinoma of the female urethra treated by multimodal therapy]
Carcinoma, Transitional Cell
Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience.
[A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report]
Cardiomegaly
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats.
Gene therapy for hypertension: a review of potential targets.
Protective actions of human tissue kallikrein gene in transgenic rat hearts.
Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene.
Serine proteases and cardiac function.
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.
Cardiomyopathies
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Cardiovascular Abnormalities
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice.
Cardiovascular Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Factors that may affect the measurement of prostate specific antigen levels in patients with cardiovascular disease. Letter to the Editor.
Perceived discrimination and use of preventive health services.
Serine proteases and cardiac function.
Carotid Artery Diseases
Circulating tissue kallikrein levels correlate with severity of carotid atherosclerosis.
Cerebral Hemorrhage
[Association of single nucleotide polymorphisms of kallikrein 1 gene with cerebral hemorrhage in Changsha Han Chinese]
Cerebral Infarction
Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction.
Experimental therapy with tissue kallikrein against cerebral ischemia.
Human Tissue Kallikrein Promoted Activation of the Ipsilesional Sensorimotor Cortex after Acute Cerebral Infarction.
Influences of urinary kallidinogenase on neuronal apoptosis in cerebral infarction rats through Nrf2/ARE oxidative stress pathway.
Remodeling of motor cortex function in acute cerebral infarction patients following human urinary kallidinogenase: A functional magnetic resonance imaging evaluation after 6 months.
Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction.
Cerebrovascular Disorders
Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases.
Choroidal Neovascularization
Tissue kallikrein attenuates choroidal neovascularization via cleavage of vascular endothelial growth factor.
Colitis
Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats.
Colitis, Ulcerative
Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Colonic Neoplasms
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly.
Colorectal Neoplasms
Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
PS3-42: Health Literacy and Cancer Prevention: It's Not What You Say It's What They Hear.
Screening for cancer. Is it useful?
Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role.
Colorectal Neoplasms, Hereditary Nonpolyposis
Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Confusion
Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
Connective Tissue Diseases
Anionic salivary proteins associated with connective tissue disorders: sialated tissue kallikreins.
Coronary Artery Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Association between angiographically assessed coronary artery disease and serum levels of prostate specific antigen.
Elevation of the serum total and free prostate specific antigen levels after stent implantation in patients with coronary artery disease.
Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease.
Prevalence and associated factors for dipstick microscopic hematuria in men.
Relation of plasma tissue kallikrein levels to presence and severity of coronary artery disease in a chinese population.
Tissue kallikrein is related to the severity of coronary artery disease.
Coronary Disease
[Improving drug therapy in circulatory insufficiency: the role of renal kallikrein-kinin system]
Cough
Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States.
Mechanism of irritant-induced cough: studies with a kinin antagonist and a kallikrein inhibitor.
COVID-19
Prostate specific antigen in COVID-19 patients.
Cranial Nerve Diseases
Bilateral third and unilateral sixth nerve palsies as early presenting signs of metastatic prostatic carcinoma.
Crohn Disease
Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Cystic Fibrosis
Comparative studies on salivary kallikrein from cystic fibrosis patients and controls.
Cystitis
Prostate specific antigen and acid phosphatase-reactive cells in cystitis cystica and glandularis.
Cysts
Histopathological study of the müllerian duct remnant: clarification of disease categories and terminology.
Dengue
A propeptide-independent protease from Tannerella sp.6_1_58FAA_CT1 displays trypsin-like specificity.
Steady-state cleavage kinetics for dengue virus type 2 ns2b-ns3(pro) serine protease with synthetic peptides.
Dermatitis, Atopic
Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients.
Dextrocardia
Incidental Finding of Dextrocardia with Situs Inversus in a 59-Year-Old Man.
Diabetes Complications
Protease profiling of different biofluids in type 1 diabetes mellitus.
Diabetes Mellitus
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Anorectal application of 5% lidocaine cream reduces pain prior to periprostatic nerve block during transrectal ultrasound guided prostate biopsy: Randomized, prospective controlled study.
Effects of Urinary Kallidinogenase on NIHSS score, mRS score, and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism: A prospective cohort study.
Human tissue kallikrein: a new bullet for the treatment of ischemia.
Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Urinary kallikrein excretion in insulin-dependent diabetes mellitus and its relationship to glycemic control.
[Method for determining kallikrein of tissue origin in blood plasma and its clinical significance]
Diabetes Mellitus, Experimental
Renal kallikrein in human and experimental diabetes mellitus.
Diabetes Mellitus, Type 1
Human Tissue Kallikrein 1 Improves Erectile Dysfunction of Streptozotocin-Induced Diabetic Rats by Inhibition of Excessive Oxidative Stress and Activation of the PI3K/AKT/eNOS Pathway.
Increased tissue kallikrein amidase activity in urine of patients with type 1 diabetes under insulin therapy, and in those with gestational diabetes mellitus not under insulin therapy.
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Protease profiling of different biofluids in type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Increased tissue kallikrein levels in type 2 diabetes.
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study.
Diabetes, Gestational
Increased tissue kallikrein amidase activity in urine of patients with type 1 diabetes under insulin therapy, and in those with gestational diabetes mellitus not under insulin therapy.
Diabetic Angiopathies
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Diabetic Cardiomyopathies
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene.
Diabetic Nephropathies
Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats.
Kallikrein protects against microalbuminuria in experimental type I diabetes.
Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy.
[Renal kallikrein in diabetic nephropathy]
Diabetic Retinopathy
Levels of human tissue kallikrein in the vitreous fluid of patients with severe proliferative diabetic retinopathy.
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Disorders of Sex Development
Prostate screening in patients with 46,XY disorders of sex development--is it necessary?
Disseminated Intravascular Coagulation
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
Diverticulitis
Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
Diverticulum
Patient selection and counseling before prostatic arterial embolization.
Drug-Related Side Effects and Adverse Reactions
Efficacy of flutamide-combined androgen blockade therapy in advanced prostate cancer patients: a phase III randomized, comparative trial.
Dwarfism, Pituitary
Prostate biopsy free system for laparoscopic radical prostatectomy in a pituitary dwarfism: a case report.
Dyspnea
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
End Stage Liver Disease
[Influence of renal and hepatic function in the serum concentration of prostate specific antigen]
Endotoxemia
Effects of gabexate mesilate on coagulopathy and organ dysfunction in rats with endotoxemia: a potential use of thrombelastography in endotoxin-induced sepsis.
Enterocolitis
Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats.
Epilepsy
Evaluation of inflammatory kinin-forming components in experimental epilepsy in rats.
Kallikrein 1 is overexpressed by astrocytes in the hippocampus of patients with refractory temporal lobe epilepsy, associated with hippocampal sclerosis.
Epilepsy, Temporal Lobe
Kallikrein 1 is overexpressed by astrocytes in the hippocampus of patients with refractory temporal lobe epilepsy, associated with hippocampal sclerosis.
Epiretinal Membrane
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Erectile Dysfunction
2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction.
Adaptive spaced education improves learning efficiency: a randomized controlled trial.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial.
Development and initial evaluation of a novel urology curriculum for medical students.
Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education.
Erectile dysfunction and testosterone screening with prostate specific antigen screening at age 40: are these three gender specific determinants additive for overall men's heath and do they improve traditional non-gender specific determinants to lessen cardiovascular risk and all-cause mortality?
Human tissue kallikrein 1 ameliorates erectile function via modulation of macroautophagy in aged transgenic rats.
Human Tissue Kallikrein 1 Improves Erectile Dysfunction of Streptozotocin-Induced Diabetic Rats by Inhibition of Excessive Oxidative Stress and Activation of the PI3K/AKT/eNOS Pathway.
Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial.
Laboratory evaluations of erectile dysfunction: an evidence based approach.
Preserved Erectile Function in the Aged Transgenic Rat Harboring Human Tissue Kallikrein 1.
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Reduced corporal fibrosis to protect erectile function by inhibiting the Rho-kinase/LIM-kinase/cofilin pathway in the aged transgenic rat harboring human tissue kallikrein 1.
The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.
The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.
The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Escherichia coli Infections
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Re: Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Esophageal Squamous Cell Carcinoma
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Essential Hypertension
A coding polymorphism of the kallikrein 1 gene is associated with essential hypertension: a tagging SNP-based association study in a Chinese Han population.
Acute effect of furosemide on renal kallikrein and prostaglandin systems in mild to moderate essential hypertension.
An ontogenic study of renal tissue kallikrein in Okamoto spontaneously hypertensive rats: comparisons with human hypertensive nephropathy.
Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study.
Comparative hypertensionology-renal dopaminergic activity in experimental hypertensive rats.
Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.
DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene.
Effect of upright tilting on kinins as compared to renin activity in the renal venous blood from patients with essential hypertension.
Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension.
Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension.
Examination of the role of nitric oxide synthase and renal kallikrein as candidate genes for essential hypertension.
Gender differences of human tissue kallikrein and an erythrocyte kallikrein-like enzyme in essential hypertension.
Impaired renal kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.
Is the renal kallikrein system relevant to sodium sensitivity in patients with essential hypertension.
Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertension.
Natriuretic effect of acute nifedipine administration is not mediated by the renal kallikrein-kinin system.
Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.
Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension.
Renal kallikrein-kinin system and prostaglandin in hypertension: their relation to renin-angiotensin-aldosterone system.
Salivary kallikrein excretion in hypertension.
The excretion of human urinary kallikrein quantity and activity in normal and low renin subgroups of essential hypertension.
Urinary excretions of kininase I and kininase II activities in essential hypertension. A sensitive and simple method for its kinin-destroying capacity.
Extranodal Extension
18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.
Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor.
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features.
Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.
Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival.
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy.
Factors affecting surgical margin positivity in robotic assisted radical prostatectomy.
Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
Is year of radical prostatectomy a predictor of outcome in prostate cancer?
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Nerve advancement with end-to-end reconstruction after partial neurovascular bundle resection:a feasibility study.
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
Prediction of focal extracapsular extension at radical prostatectomy: Relative merit of transrectal ultrasound, endorectal magnetic resonance imaging, prostate specific antigen, prostate specific antigen density, and systematic biopsy.
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Prognostic utility of neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio in predicting biochemical recurrence post robotic prostatectomy.
Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer.
Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database.
The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer.
The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy.
The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Siddiqui MM, Shakir NA, Okoro C, Rothwax JT, Walton-Diaz A, Sankineni S, Su D, Stamatakis L, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; e-mail: pintop@mail.nih.gov.J Urol. 2015 Jul;194(1):105-11. [Epub 2015 Jan 23]. doi: 10.1016/j.juro.2015.01.072.
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens.
Fibrocystic Breast Disease
Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease.
Prostate specific antigen- PSA in women with menstrual disturbances and fibrocystic mastopathy.
Fowlpox
A Phase I Trial of Pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in Patients with Prostate Cancer.
Gastritis
Correlation of kinin generating activity with Helicobacter pylori-associated gastric infection.
[Role of tissue kallikrein in chronic gastritis]
Gastritis, Atrophic
Significance of tissue kallikrein in chronic atrophic gastritis.
Gastroesophageal Reflux
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Gastrointestinal Neoplasms
Increasing the sensitivity of enzyme-linked immunosorbent assay using multiplexed electrokinetic concentrator.
Gastrointestinal Stromal Tumors
Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.
Glaucoma
Impact of a patient incentive program on receipt of preventive care.
Glioma
Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays.
Phase I study of phenylacetate administered twice daily to patients with cancer.
Glomerulonephritis
Renal kallikrein and PGE in the exaggerated fractional Na excretion in patients with chronic renal failure.
[Components of kallikrein-kinin system in the urine of patients with glomerulonephritis]
Glucose Intolerance
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Gonorrhea
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Granuloma
Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Iatrogenic granulomas of the prostate and the urinary bladder.
Localization and secretion of tissue kallikrein in peptidoglycan-induced enterocolitis in Lewis rats.
Gynecomastia
Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
The relationship between pubertal gynecomastia, prostate specific antigen, free androgen index, SHBG and sex steroids.
Hamartoma
Isolated metastasis to a pulmonary hamartoma.
Hand-Foot Syndrome
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Heart Diseases
Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers.
Online, Interactive Option Grid Patient Decision Aids and their Effect on User Preferences.
Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Update on the safety of testosterone therapy in cardiac disease.
Heart Failure
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease.
Serine proteases and cardiac function.
Heart Failure, Systolic
The amidase activity of human tissue kallikrein is significantly lower in the urine of patients with systolic heart failure.
Hematuria
Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.
Deficits in urological knowledge among medical students and primary care providers: potential for impact on urological care.
Ductal prostatic adenocarcinoma: magnetic resonance imaging documenting the effect of hormone-radiotherapy.
Holmium Laser Enucleation vs Bipolar Plasmakinetic Enucleation of a Large Volume Benign Prostatic Hyperplasia: A Randomized Controlled Trial.
Safety of 12 core transrectal ultrasound guided prostate biopsy in patients on aspirin.
Urological knowledge among primary health care physicians in Saudi Arabia.
Hemianopsia
[A Case of Primary Central Nervous System Lymphoma that Developed during the Treatment of Castration-Resistant Prostate Cancer].
Hemospermia
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
Safety of 12 core transrectal ultrasound guided prostate biopsy in patients on aspirin.
Hepatitis
Impact of Laboratory Test Use Strategies in a Turkish Hospital.
Prostatic acid phosphatase and prostate specific antigen in liver disease.
Hepatitis C
Analysis of interaction between RNA aptamer and protein using nucleotide analogs.
Redesigning the substrate specificity of the hepatitis C virus NS3 protease.
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.
Understanding preventive health screening services use in persons with serious mental illness: how does integrated behavioral health primary care compare?
Hepatitis, Chronic
Prostatic acid phosphatase and prostate specific antigen in liver disease.
[Method for determining kallikrein of tissue origin in blood plasma and its clinical significance]
Herpes Zoster
A delayed sperm penetration of cumulus layers by disruption of acrosin gene in rats.
HIV Infections
Recent Semen Exposure Impacts the Cytokine Response and Bacterial Vaginosis in Women.
Hyperaldosteronism
Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse.
Direct hypotensive action of intravascular bradykinin in man.
Hyperandrogenism
A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.
Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome - a new insight.
Hyperglycemia
Effects of aprotinin on the kallikrein-kinin system in type I diabetes (insulitis).
Hyperinsulinism
Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation.
Changes of glandular kallikrein activity in human plasma following glucose ingestion.
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.
Hyperkalemia
Partial genetic deficiency in tissue kallikrein impairs adaptation to high potassium intake in humans.
Hypersensitivity
Change in tissue kallikrein level in nasal wash after the administration of oxatomide in patients with nasal allergy.
Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis.
Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
[Kinins and kallikrein in nasal secretion after antigen challenge in patients with allergic rhinitis]
Hypertension
A missing link between a high salt intake and blood pressure increase.
A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.
Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats.
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
An ontogenic study of renal tissue kallikrein in Okamoto spontaneously hypertensive rats: comparisons with human hypertensive nephropathy.
Association of the tissue kallikrein gene promoter with ESRD and hypertension.
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice.
Cation excretion and kallikrein secretion by the rat parotid gland in various hypertensive models.
Cellular and functional aspects of the renal kallikrein system in health and disease.
Changes in urinary tissue kallikrein excretion in black African women with hypertensive disorders of pregnancy.
Comparison of Clinical and Physiological Parameters for Benign Prostatic Hyperplasia in Hypertensive and Normotensive Patients.
Cosegregation of blood pressure with a kallikrein gene family polymorphism.
Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension.
Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats.
Effect of mycophenolate mofetil on kallikrein expression in the kidney of 5/6 nephrectomized rats.
Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases.
Expression of the renal kallikrein gene in mineralocorticoid-treated and genetically hypertensive rats.
Gender differences of human tissue kallikrein and an erythrocyte kallikrein-like enzyme in essential hypertension.
Gene therapy for hypertension: a review of potential targets.
Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats.
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.
Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats.
Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats.
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
Human Urinary kallidinogenase promotes good recovery in ischemic stroke patients with level 3 hypertension.
Immunoreactive glandular kallikrein in plasma during alterations of urinary kallikrein excretion.
Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Increased tissue kallikrein amidase activity in urine of patients with type 1 diabetes under insulin therapy, and in those with gestational diabetes mellitus not under insulin therapy.
Independent, marked associations of alleles of the insulin receptor and dipeptidyl carboxypeptidase-I genes with essential hypertension.
Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats.
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats.
Kallikrein genes: cloning in man and expression in rat renal hypertension.
Kallikrein-kinin in stroke, cardiovascular and renal disease.
Kallikrein-kinin system in severe experimental hypertension.
KLK1 A1789G gene polymorphism and the risk of coronary artery stenosis in the Chinese population.
Lack of oral kallikrein in lowering systemic blood pressure in primary hypertension.
Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertension.
Modulation of renal kallikrein by a high potassium diet in rats with intense proteinuria.
Modulation of renin-angiotensin and kallikrein gene expression in experimental hypertension.
New experimental evidence for a role of tissue kallikrein in hypertension.
Prevalence and associated factors for dipstick microscopic hematuria in men.
Prolonged hypotensive effect of human tissue kallikrein gene delivery and recombinant enzyme administration in spontaneous hypertension rats.
Protective effect of cicletanine on hypertension-induced decreases in the renal kallikrein-kinin and prostaglandin systems in stroke-prone spontaneously hypertensive rats.
Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension.
Purification of human tissue prokallikrein excreted from insect cells by liquid chromatography.
Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.
Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure.
Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension.
Renal functional reserve in obesity hypertension.
Renal kallikrein activity in rats developing spontaneous hypertension.
Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension.
Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy.
Renal kallikrein in human and experimental diabetes mellitus.
Renal kallikrein system, volemia, and renal hypertension.
Renal phenotype of low kallikrein rats.
Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes.
Salivary kallikrein excretion in hypertension.
Serine proteases and cardiac function.
Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system.
Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats.
Taurine amplifies renal kallikrein and prevents salt-induced hypertension in Dahl rats.
The "silver-haired" general medical services patient. Clinical activity of the non-means tested over-70's during their first six months.
The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study.
The renal kallikrein-kinin system in renoparenchymal hypertension.
The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension.
The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction.
Tissue kallikrein deficiency and renovascular hypertension in the mouse.
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.
Urinary and renal kallikrein in hypertensive fawn-hooded (FH/Wjd) rats.
[Changes in the activity of renal intracortical kallikrein during induction of Goldblatt arterial hypertension of the 2 kidney--1 clip type in the rat]
[Kallikrein (urine) in pregnancy-induced hypertension]
Hypertension, Pregnancy-Induced
Tissue kallikrein and kininogen levels in fetoplacental tissues from normotensive pregnant women and women with pregnancy-induced hypertension.
Hypertension, Renal
Renal kallikrein activity and urinary kallikrein excretion in rats with experimental renal hypertension.
Renal kallikrein system, volemia, and renal hypertension.
Renal tissue kallikrein, plasma renin and plasma aldosterone in renal hypertension.
Hypertension, Renovascular
Cation excretion and kallikrein secretion by the rat parotid gland in various hypertensive models.
Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats.
Tissue kallikrein deficiency and renovascular hypertension in the mouse.
[Renal kallikrein: variations in relation to sodium intake and experimental renovascular hypertension (author's transl)]
Hypertrophy, Left Ventricular
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Hypogonadism
Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism.
Oral testosterone replacement in Korean patients with PADAM.
Testosterone replacement therapy in male hypogonadism.
The Ratio of Serum Testosterone-to-Prostate Specific Antigen Predicts Prostate Cancer in Hypogonadal Men.
[A case of progressive prostatic carcinoma in a patient with acquired hypogonadism.]
Hypoparathyroidism
FAM111A induces nuclear dysfunction in disease and viral restriction.
Hypotension
High level expression of human tissue kallikrein in the circulation induces hypotension in transgenic mice.
High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model.
Human tissue kallikrein induces hypotension in transgenic mice.
Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein.
Kallikrein, kininogen and kinins in control of blood pressure.
Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats.
Inappropriate ADH Syndrome
Increased renal kallikrein excretion in SIADH after vincristine therapy.
Infarction, Middle Cerebral Artery
Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats.
Intra-arterial human urinary kallidinogenase alleviates brain injury in rats with permanent middle cerebral artery occlusion through PI3K/AKT/FoxO1 signaling pathway.
Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis.
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.
The Long-Term Outcome Comparison of Different Time-Delayed Kallikrein Treatments in a Mouse Cerebral Ischemic Model.
Infections
Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery.
Association of schistosomiasis and risk of prostate cancer development in residents of Murehwa rural community, Zimbabwe.
Correlation of kinin generating activity with Helicobacter pylori-associated gastric infection.
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Experimental Rhinovirus Infection Increases Human Tissue Kallikrein Activation in Allergic Subjects.
Involvement of proteases in porcine reproductive and respiratory syndrome virus uncoating upon internalization in primary macrophages.
Patient selection and counseling before prostatic arterial embolization.
Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Prostate specific antigen in urinary tract infection.
Re: Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis.
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration.
Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection.
Upregulation of a Trypsin-Like Serine Protease Gene in Antheraea pernyi (Lepidoptera: Saturniidae) Strains Exposed to Different Pathogens.
[Markers for diagnosis, prediction and prognosis of prostate cancer]
Infertility
Successful fertility treatment with gonadotrophin therapy for male hypogonadotrophic hypogonadism.
Infertility, Male
Genetic association study of a single nucleotide polymorphism of kallikrein-related peptidase 2 with male infertility.
Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility.
Successful fertility treatment with gonadotrophin therapy for male hypogonadotrophic hypogonadism.
Inflammatory Bowel Diseases
Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Influenza, Human
A top 5 list for French general practice.
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
Quantification of antigen by digital domain analysis of integrated nanogap biosensors.
The "silver-haired" general medical services patient. Clinical activity of the non-means tested over-70's during their first six months.
Tissue kallikrein regulates alveolar macrophage apoptosis early in influenza virus infection.
Understanding preventive health screening services use in persons with serious mental illness: how does integrated behavioral health primary care compare?
When a usual source of care and usual provider matter: adult prevention and screening services.
Insulin Resistance
A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.
Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats.
Prostate specific antigen mass ratio potential as a prostate cancer screening tool.
Tissue kallikrein deficiency, insulin resistance and diabetes in mouse and man.
Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.
Intracranial Aneurysm
Effect of HUK on the outcome of ruptured intracranial aneurysm.
Ischemic Stroke
Effects of Urinary Kallidinogenase on NIHSS score, mRS score, and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism: A prospective cohort study.
Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis.
Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: A systematic review.
Exogenous human urinary kallidinogenase increases cerebral blood flow in patients with acute ischemic stroke.
Experimental therapy with tissue kallikrein against cerebral ischemia.
High Level of Serum Tissue Kallikrein Is Associated with Favorable Outcome in Acute Ischemic Stroke Patients.
Human tissue kallikrein in the treatment of acute ischemic stroke.
Human Tissue Kallikrein Promoted Activation of the Ipsilesional Sensorimotor Cortex after Acute Cerebral Infarction.
Human Urinary Kallidinogenase decreases recurrence risk and promotes good recovery.
Human urinary kallidinogenase in acute ischemic stroke: A single-arm, multicenter, phase IV study (RESK study).
Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial.
Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke.
Human Urinary kallidinogenase promotes good recovery in ischemic stroke patients with level 3 hypertension.
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients.
Remote limb ischemic postconditioning promotes motor function recovery in a rat model of ischemic stroke via the up-regulation of endogenous tissue kallikrein.
The Pyk2/MCU Pathway in the Rat Middle Cerebral Artery Occlusion Model of Ischemic Stroke.
The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction.
Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases.
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-?B and activating Nrf2 signaling pathway in rats.
Treatment of Human Urinary Kallidinogenase Combined with Maixuekang Capsule Promotes Good Functional Outcome in Ischemic Stroke.
Kidney Failure, Chronic
Association of the tissue kallikrein gene promoter with ESRD and hypertension.
Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats.
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
Patient selection and counseling before prostatic arterial embolization.
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
Prostate cancer in renal transplant recipients.
Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease.
Renal kallikrein and PGE in the exaggerated fractional Na excretion in patients with chronic renal failure.
Role of renal kallikrein in the increased fractional sodium excretion in the rat remnant kidney model of chronic renal failure.
Role of renal kallikrein in the regulation of blood pressure in the rat remnant kidney model of chronic renal failure.
Serum tumor markers in hemodialysis patients.
[Influence of renal and hepatic function in the serum concentration of prostate specific antigen]
[Tumour markers in chronic kidney disease.]
Leiomyosarcoma
Prostate Leiomyosarcoma: A Rare Misleading Tumor.
Leukemia
T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report.
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
Liver Cirrhosis
Prostatic acid phosphatase and prostate specific antigen in liver disease.
[Excretion of renal kallikrein in liver cirrhosis]
Liver Cirrhosis, Alcoholic
Renal kallikrein excretion in alcoholic cirrhosis. Relationship to other vasoactive systems.
Liver Diseases
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Prostatic acid phosphatase and prostate specific antigen in liver disease.
Liver Neoplasms
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.
Lung Neoplasms
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer.
KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer.
Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA.
Lupus Erythematosus, Systemic
Kallikreins and lupus nephritis.
Lupus Nephritis
Kallikreins and lupus nephritis.
Kinin system in lupus nephritis.
Lymphadenopathy
Metastatic prostate carcinoma presenting as supraclavicular lymphadenopathy - is it unusual?
Lymphatic Metastasis
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
Contemporary appraisal of radical perineal prostatectomy.
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy.
Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Increased SPC24 in prostatic diseases and diagnostic value of SPC24 and its interacting partners in prostate cancer.
Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?
Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Positron emission tomography in urological oncology.
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Radioisotope guided pelvic lymph node dissection for prostate cancer.
Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer.
Return of serum prostate specific antigen to undetectable level following removal of solitary lymph node metastasis.
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.
The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.
Treatment of the positive surgical margin following radical prostatectomy.
[Giant Prostate Carcinoma : A Case Report and Long-Term Outcomes in Japanese Patients].
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
Lymphocytosis
Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.
Lymphoma
Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate.
Kallikrein-kinin system in patients with neoplastic diseases.
T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report.
Malnutrition
Role of bradykinin B2 receptors in neonatal kidney growth.
Meckel Diverticulum
Incidental possible diagnosis by 18F-fluorocholine PET/CT of Meckel's diverticulum and potential pitfalls.
Melanoma
A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Immunocytochemical detection of prostate specific antigen expression in human primary and metastatic melanomas.
Meningioma
Metastatic prostatic adenocarcinoma with neuroendocrine differentiation to meningioma.
Metabolic Syndrome
The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
Microphthalmos
Autosomal-Recessive Posterior Microphthalmos Is Caused by Mutations in PRSS56, a Gene Encoding a Trypsin-Like Serine Protease.
Mouth Neoplasms
Dielectrophoretic label-free immunoassay for rare-analyte quantification in biological samples.
Myocardial Infarction
Acute myocardial infarction without cardiogenic shock does not affect serum prostate specific antigen levels: A case control study.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Analyses of mutations in the human renal kallikrein (hKLK1) gene and their possible relevance to blood pressure regulation and risk of myocardial infarction.
New perspective on the tissue kallikrein-kinin system in myocardial infarction: role of angiogenesis and cardiac regeneration.
Prostate specific antigen levels after acute myocardial infarction.
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.
Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice.
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.
Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.
Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity.
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway.
Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis.
Myocardial Ischemia
Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.
Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Tissue kallikrein is required for the cardioprotective effect of Cyclosporin A in myocardial ischemia in the mouse.
Nasopharyngitis
A top 5 list for French general practice.
Neoplasm Metastasis
(68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.
(99m)Tc-MDP uptake in SPECT/CT by a bladder hernia simulating inguinal metastasis: A case report.
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy.
A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells.
A pilot study of intermittent androgen deprivation in advanced prostate cancer.
A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up.
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
Assay for prostate specific antigen (PSA): problems and possible solutions.
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Autoantibodies to prostasomes as new markers for prostate cancer.
Bicalutamide: in early-stage prostate cancer.
Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
Can radiotherapy salvage isolated local recurrence following radical prostatectomy?
Can the need for palliative transurethral prostatic resection in patients with advanced carcinoma of the prostate be predicted?
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years.
Cancer control following anatomical radical prostatectomy: an interim report.
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis.
Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy.
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts.
Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
Contemporary appraisal of radical perineal prostatectomy.
Correlation between bone metabolic markers and bone scan in prostatic cancer.
Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans?
Current treatment of non-metastatic castration-refractory prostate cancer.
Cytogenetics and Molecular Genetics of Prostate Cancer: A Comprehensive Update.
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound.
Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels.
Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.
Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile.
Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy.
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level.
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.
Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Embryonal carcinoma of the testis associated with prostate cancer in a 72-year-old man.
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Establishment of human prostate carcinoma skeletal metastasis models.
Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.
Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.
Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms.
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Expression of Telomere Repeat Binding Factor 1 and TRF2 in Prostate Cancer and Correlation with Clinical Parameters.
Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer.
Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy.
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer.
High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago Prostate Survey.
High dose rate brachytherapy for prostate cancer.
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Historical prostate cancer screening and treatment outcomes from a single institution.
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report.
Imaging of prostate cancer.
Imaging of prostate carcinoma.
Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues.
Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
Increased SPC24 in prostatic diseases and diagnostic value of SPC24 and its interacting partners in prostate cancer.
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Interactions between human osteoblasts and prostate cancer cells in a novel 3D in vitro model.
Interleukin-1? promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Interstitial high-dose-rate brachytherapy as a boost in synchronous prostate and rectal cancer treatment: case report and literature review.
Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?
Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?
Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.
Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen.
Laparoscopic port-site metastasis as the manifestation of neuroendocrine prostate cancer: Case report and literature review.
Late recurrence of adenoid cystic carcinoma of the prostate.
Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis.
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.
Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy.
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy.
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Metastasis on Bone Scan With Low Prostate Specific Antigen (? 20 ng/ml) and Gleason's Score (<8) in Newly Diagnosed Pakistani Males with Prostate Cancer: Should We Follow Western Guidelines?
Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
Morphometric and clinical studies on 68 consecutive radical prostatectomies.
MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID.
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy.
Paraneoplastic bleeding disorder due to isolated hypofibrinogenemia: A case report.
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels.
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Piflufolastat F 18: Diagnostic First Approval.
Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.
Positron emission tomography in urological oncology.
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy.
Predictive values of miR-129 and miR-139 for efficacy on patients with prostate cancer after chemotherapy and prognostic correlation.
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.
Prevalence of lymph node metastasis in radical prostatectomy; a retrospective and multicenter study in iran.
Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment.
Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy.
Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy.
Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen.
Prostate specific antigen after irradiation for prostatic carcinoma.
Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design.
Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting (18)F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy.
Prostate-specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-control Study.
Prostatic metastases in the nose and paranasal sinuses.
Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Radioisotope guided pelvic lymph node dissection for prostate cancer.
Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study.
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer.
Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Re: Strategy for Detection of Prostate Cancer Based on Relation Between Prostate Specific Antigen at Age 40-55 and Long Term Risk of Metastasis: Case-control Study.
Receptor gene messenger RNA expression in metastatic lesions of prostate cancer.
Return of serum prostate specific antigen to undetectable level following removal of solitary lymph node metastasis.
Risk of prostate carcinoma death in patients with lymph node metastasis.
Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation.
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis.
Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.
Small cell metastatic prostate cancer with ectopic adrenocorticotropic hormone hypersecretion.
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.
Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma.
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy.
Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer.
Surgical approaches to local failure after definitive therapy.
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.
The Benefit of a Surgical Resection of a Solitary Pulmonary Metastasis of Prostate Cancer after Radical Prostatectomy.
The Effect of Radium-223 Therapy in Agent Orange-Related Prostate Carcinoma.
The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate.
The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy.
The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.
The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone.
The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis.
The utility of bone remodeling markers in the diagnosis, evolution and treatment response evaluation in bone metastases.
The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Tibia metastasis without prostate specific antigen (PSA) increase following radical vesiculo-prostatectomy.
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome.
Treatment of the positive surgical margin following radical prostatectomy.
Tumor fraction in cell-free DNA as a biomarker in prostate cancer.
Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
Unresolving / progressive skin lesions in cancer patients: be aware of carcinoma cutis.
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy.
Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
[A Case of de novo Neuroendocrine Prostate Cancer].
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
[A case of prostatic ductal adenocarcinoma with endometrioid features, associated with rectal invasion and multiple liver metastases]
[A case of solitary endobronchial metastasis of prostatic cancer]
[Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival]
[CLINICAL STUDY OF THE PROSTATE CANCERS WITH A SERUM PROSTATE SPECIFIC ANTIGEN LEVEL OF MORE THAN 100 ng/ml AT THE FIRST DIAGNOSIS].
[Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the literature]
[Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]
[Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma]
[Diagnostic imaging of the prostate cancer].
[Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease]
[Ganglion curage in prostate cancer]
[Giant Prostate Carcinoma : A Case Report and Long-Term Outcomes in Japanese Patients].
[Is it possible to do without bone gammagraphy in the staging of prostatic cancer?]
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
[Local recurrence after radical prostatectomy and salvage radiotherapy]
[Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report].
[Ophthalmoplegia in a patient with prostate cancer and bone metastases]
[Predictive factors for bone metastases of prostate cancer].
[Prostate cancer recurrence after radical prostatectomy and salvage radiotherapy]
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]
[Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]
[Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
[When should bone scanning be carried out in prostatic cancer?]
Neoplasm Micrometastasis
Novel imaging in advanced prostate cancer.
Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients.
The application of the RT-PCR method for the staging of the prostate cancer progression.
Neoplasm, Residual
A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy.
Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.
Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography.
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen.
Impact of margin size on the incidence of local residual tumor after laparoscopic radical prostatectomy.
LncRNA SNHG9 is a prognostic biomarker and correlated with immune infiltrates in prostate cancer.
Outcomes Post Neoadjuvant Intense Hormone Therapy and Surgery for Patients with High-Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
The predictive significance of substaging stage A prostate cancer (A1 versus A2) for volume and grade of total cancer in the prostate.
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
Neoplasms
"Robotic fatigue?" - The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy.
'Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases.
25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate.
5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk?
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
5alpha-reductase 2 polymorphisms as risk factors in prostate cancer.
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.
A case of Sister Mary Joseph's nodule from prostatic cancer.
A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects.
A cell kinetics model for prostate cancer and its application to clinical data and individual patients.
A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.
A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer.
A comparison of the biological features between prostate cancers arising in the transition and peripheral zones.
A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy.
A critical comparison of techniques for MRI-targeted biopsy of the prostate.
A guideline to clinical utility of prostate specific antigen.
A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations.
A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy.
A Modified Partin Table to Better Predict Extracapsular Extension in Clinically Localized Prostate Cancer.
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System.
A nanoplasmonic biosensor for label-free multiplex detection of cancer biomarkers.
A new human prostate carcinoma cell line, 22Rv1.
A new serially transplantable human prostatic cancer (HONDA) in nude mice.
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.
A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results.
A novel biopsy-related parameter derived from location and relationship of positive cores on standard 12-core trans-rectal ultrasound-guided prostate biopsy: a useful parameter for predicting tumor volume compared to number of positive cores.
A novel immunosensor for the monitoring of PSA using binding of biotinylated antibody to the prostate specific antigen based on nano-ink modified flexible paper substrate: efficient method for diagnosis of cancer using biosensing technology.
A novel label-free colorimetric aptasensor for sensitive determination of PSA biomarker using gold nanoparticles and a cationic polymer in human serum.
A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor.
A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection.
A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate.
A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup.
A review of the role of established tumour markers.
A Review on the Clinical Utility of PSA in Cancer Prostate.
A simple computer program for calculating PSA recurrence in prostate cancer patients.
A survival model for fractionated radiotherapy with an application to prostate cancer.
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
A systematic review of brachytherapy. Is it an effective and safe treatment for localised prostate cancer?
A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer.
A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies.
A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
Active surveillance for low-risk localized prostate cancer: what do men and their partners think?
Active surveillance for low-risk prostate cancer.
Active surveillance: towards a new paradigm in the management of early prostate cancer.
Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors.
Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report.
Adenosquamous carcinoma of the prostate.
Adjuvant radiotherapy for high-risk patients following radical prostatectomy.
Adverse prognostic significance of capsular incision with radical retropubic prostatectomy.
African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance.
African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations.
Aligned carbon nanotubes on quartz substrate for liquid gated biosensing.
American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen.
Amplified binding-induced homogeneous assay through catalytic cycling of analyte for ultrasensitive protein detection.
An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
An aptamer based resonance light scattering assay of prostate specific antigen.
An enhanced LSPR fiber-optic nanoprobe for ultrasensitive detection of protein biomarkers.
An enhanced prognostic system for clinically localized carcinoma of the prostate.
An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a nigerian teaching hospital.
An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
An improved method for computerized tomography-planned transperineal 125iodine prostate implants.
An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.
Analysis of tumor spillage during radical prostatectomy using RT-PCR of prostate specific antigen.
Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results.
Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Antigen Specific T-Cell Responses Against Tumor Antigens are Controlled by Regulatory T Cells in Patients With Prostate Cancer.
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures.
Are multiple markers the future of prostate cancer diagnostics?
Arraying prostate specific antigen PSA and Fab anti-PSA using light assisted molecular immobilization technology.
Artificial neural network model to predict biochemical failure after radical prostatectomy.
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey.
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men.
Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Atypical case of metastatic undifferentiated prostate carcinoma in a 36 years old man: clinical report and literature review.
Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.
Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
Baseline staging of newly diagnosed prostate cancer: a summary of the literature.
Bayesian neural networks for bivariate binary data: an application to prostate cancer study.
Beyond PSA: The Role of Prostate Health Index (phi).
Bilateral cancer in prostate biopsy associates with the presence of extracapsular disease and positive surgical margins in low risk patients: a consideration for bilateral nerve sparing radical prostatectomy decision.
Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer.
Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
Biological, psychological and behavioral, and social variables influencing colorectal cancer screening in African Americans.
Biomarkers identified for prostate cancer patients through genome-scale screening.
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Cabazitaxel: A Guide to Its Use in Hormone-Refractory Metastatic Prostate Cancer.
Calculating prostate cancer volume preoperatively: the D'Amico equation and some other observations.
Can 68Ga-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy? A Pilot Study.
Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?
Cancer diagnosis with prostate specific antigen greater than 10 ng./ml. and negative peripheral zone prostate biopsy.
Cancer incidence among triazine herbicide manufacturing workers.
Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up Study.
Cancer screening in Queensland men.
Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Carbon Nanotubes Multifunctionalized by Rolling Circle Amplification and Their Application for Highly Sensitive Detection of Cancer Markers.
Catheter-less robotic radical prostatectomy using a custom-made synchronous anastomotic splint and vesical urinary diversion device: report of the initial series and perioperative outcomes.
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features.
Cerebellar metastases from prostatic carcinoma.
Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis.
Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Characteristics of patients with familial versus sporadic prostate cancer.
Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project.
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Chemoprevention of prostate cancer with nutrients and supplements.
Chemoprevention of prostate cancer.
Chemoprevention of prostate cancer: agents and study designs.
Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model.
Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer.
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts.
Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Clinical and Biochemical Influence of Prostatic Stones.
Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men.
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.
Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.
Clinical use of prostate specific antigen in patients with prostate cancer.
Clinical use of tumor markers in oncology.
Clinical usefulness of percentage of free serum prostate specific antigen.
Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.
Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.
Clinicopathological characteristics of prostatic adenocarcinoma in men with atypical prostate needle biopsies.
Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance.
Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding.
Colorimetric platform for visual detection of cancer biomarker based on intrinsic peroxidase activity of graphene oxide.
Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate.
Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy of Gleason 9-10 Prostate Cancer.
Combining diagnostic test results to increase accuracy.
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.
Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Comparative Study of Blood-Based Biomarkers, ?2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.
Comparing Revo-i and da Vinci in Retzius-sparing robot-assisted radical prostatectomy: a preliminary propensity score analysis of outcomes.
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.
Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Comparison of methods for calculating prostate specific antigen velocity.
Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.
Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
Contemporary impact of transrectal ultrasound lesions for prostate cancer detection.
Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination.
Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Contemporary trends in low risk prostate cancer: risk assessment and treatment.
Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer.
Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens.
Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP).
Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
CuO-induced signal amplification strategy for multiplexed photoelectrochemical immunosensing using CdS sensitized ZnO nanotubes arrays as photoactive material and AuPd alloy nanoparticles as electron sink.
Current status of tissue kallikrein inhibitors: importance in cancer.
Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.
Decrease in prostate specific antigen secretion correlated with docetaxel-induced growth inhibition and apoptosis in human prostate tumor cells.
Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.
Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?
Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort.
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
Demonstration of kallikrein in a rat pancreatic acinar cell carcinoma.
Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma.
Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
Designing nanomaterial-enhanced electrochemical immunosensors for cancer biomarker proteins.
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Detection of cancer biomarkers by piezoelectric biosensor using PZT ceramic resonator as the transducer.
Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor.
Detection of cancer by tumor markers in the blood: a view to the future.
Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers.
Determination of prostate volume with transrectal ultrasound for cancer screening. Part I. Comparison with prostate specific antigen assays.
Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy.
Development of Novel Piezoelectric Biosensor Using PZT Ceramic Resonator for Detection of Cancer Markers.
Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL.
Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies.
Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4.
Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Diffusion-weighted MRI for monitoring tumor response to photodynamic therapy.
Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology.
Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Disproportionate presentation of high risk prostate cancer in a safety net health system.
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies.
DNA Repair System and Prostate Cancer Progression: The Role of NBS1 Polymorphism (rs1805794).
Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 Prostate Cancer?
Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis.
Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Patients with Advanced Prostate Cancer?
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database.
Does prostate specific antigen density correlates with aggressiveness of the prostate cancer?
Does the Prentice criterion validate surrogate endpoints?
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates.
Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein.
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Ductal Adenocarcinoma of the Prostate: Increased Mortality Risk and Decreased Serum Prostate Specific Antigen.
Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.
Dumbbell-like Au-Fe3O4 nanoparticles as label for the preparation of electrochemical immunosensors.
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.
Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation.
Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.
Economic evaluation of prostate cancer screening test as a National Cancer Screening Program in South Korea.
Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy.
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice.
Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer.
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.
Effect of multimodal analgesia with paravertebral blocks on biochemical recurrence in men undergoing open radical prostatectomy.
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies.
Effectiveness of screening for prostate cancer.
Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies.
Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells.
Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.
Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Eight years of "Prostate Cancer Awareness Week": lessons in screening and early detection. Prostate Cancer Education Council.
Electrochemical immunosensors for cancer biomarker with signal amplification based on ferrocene functionalized iron oxide nanoparticles.
Electrochemical red-ox therapy of prostate cancer in nude mice.
Electrochemiluminescence immunosensor for tumor markers based on biological barcode mode with conductive nanospheres.
Electrochemiluminescent immunosensor for detection of protein cancer biomarkers using carbon nanotube forests and [Ru-(bpy)(3)](2+)-doped silica nanoparticles.
Elevated glandular kallikrein in estrogen-induced pituitary tumors.
Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar, India.
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
Emerging impact of quercetin in the treatment of prostate cancer.
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.
Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c.
Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients.
Establishing a prediction model for prostate cancer bone metastasis.
Establishment of human prostate carcinoma skeletal metastasis models.
Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models.
Evaluating diagnostic strategy of older patients with unexplained unintentional body weight loss: A hospital-based study.
Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma.
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.
Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Evaluation of MARK BTM for Quantitative Measurement of Three Tumor Markers: Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen.
Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.
Evaluation of prostate specific antigen as a tumor marker in cancer prostate.
Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma.
Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.
Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.
Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases.
Ex vivo ?H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity.
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.
Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.
Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center.
Exploration of the diagnostic value and molecular mechanism of miR?1 in prostate cancer: A study based on meta?analyses and bioinformatics.
Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Expression of ARHGAP10 correlates with prognosis of prostate cancer.
Expression of E-cadherin in primary prostate cancer: correlation with clinical features.
Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes.
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Expression of prostate specific antigen in male breast cancer.
Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Expression of the multidrug resistance gene in human prostate cancer.
Expression of the prostate specific antigen gene by lung tissue.
Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer.
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.
Extended pelvic lymphadenectomy in patients with clinically localised prostate cancer: A prospective observational study.
Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
Extracting tumour prognostic factors from a diverse electronic record dataset in genito-urinary oncology.
Extraperitoneal endoscopic pelvic lymph node dissection: a review of 125 patients.
Extraprostatic production of prostate specific antigen is under hormonal control.
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Factors predicting prostatic biopsy Gleason sum under grading.
Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence.
Failure of open radioactive 125iodine implantation to control localized prostate cancer: a study of 41 patients.
False positive values of PAP and PSA in complicated and non-complicated benign prostatic hypertrophy.
Family history and the risk of prostatic carcinoma in a high risk group of urological patients.
Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study.
Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin.
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Finasteride-its impact on sexual function and prostate cancer.
Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Focal prostate cryoablation: initial results show cancer control and potency preservation.
Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.
FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
Functional Organotypic Cultures of Prostate Tissues: A Relevant Preclinical Model that Preserves Hypoxia Sensitivity and Calcium Signaling.
Functionalized MoS2 Nanosheet-Based Field-Effect Biosensor for Label-Free Sensitive Detection of Cancer Marker Proteins in Solution.
Gel pad array chip for high throughput and multi-analyte microbead-based immunoassays.
Gene expression correlates of clinical prostate cancer behavior.
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.
Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells.
Giant dumbbell-shaped prostatic cystadenoma presenting as pelvic and scrotal mass.
Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin.
Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies.
Gleason Score 7 Prostate Cancer on Needle Biopsy: Relation of Primary Pattern 3 or 4 to Pathological Stage and Progression After Radical Prostatectomy.
GPs views and understanding of PSA testing, screening and early detection; survey.
Growth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium.
Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry.
Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis.
High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago Prostate Survey.
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study.
High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies.
Higher frequency of familial clustering of prostate cancer in French-Canadian men.
Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases.
Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes.
Histopathologic review of prostate biopsies from patients referred to a comprehensive cancer center: correlation of pathologic findings, analysis of cost, and impact on treatment.
Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Historical prostate cancer screening and treatment outcomes from a single institution.
Hormone therapy of prostatic bone metastases.
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer.
Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells.
Human tissue kallikrein gene family: applications in cancer.
Human tissue kallikreins and testicular cancer.
Human tissue kallikreins: a family of new cancer biomarkers.
Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer.
Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study.
Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate specific antigen.
Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring.
Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas.
Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation.
Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing.
Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
Imaging and Management of Prostate Cancer.
Imaging of prostate carcinoma.
Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation.
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer.
Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells.
Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations.
Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer.
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Immunosensor for the detection of cancer biomarker based on percolated graphene thin film.
Impact of increased number of biopsies on the nature of prostate cancer identified.
Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study.
Impact of organ confined prostate cancer treatment on quality of life.
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.
Impact of pre-treatment variables on the completion of 223radium-dichloride therapy in mCRPC patients with bone metastases.
Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates.
Impact of transrectal ultrasound guided prostate biopsy on quality of life: a prospective randomized trial comparing 6 versus 12 cores.
Impact of volume weighted mean nuclear volume on outcomes following salvage radiation therapy after radical prostatectomy.
Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy.
Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Important preoperative prognostic factors for extracapsular extension, seminal vesicle invasion and lymph node involvement in cases with radical retropubic prostatectomy.
Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles.
Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy.
In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.
Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival.
Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.
Increased expression of protease M in ovarian tumors.
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Increases in tumor markers are associated with primary Sjögren's syndrome-associated interstitial lung disease.
Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study.
Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Indications for laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
Indications, Utilization and Complications Following Prostate Biopsy: New York State Analysis.
Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml.
Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17?-estradiol in prostate cancer.
Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas.
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors.
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY.
Insensitivity to the growth inhibitory effects of activin A: an acquired capability in prostate cancer progression.
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.
Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma.
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: a Key Feature Towards Prodrug-Nanomedicine Design.
Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set.
Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer.
Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.
Is disease flare a problem?
Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
Is race a positive predictor of cancer on repeat prostate biopsy?
Is routine digital rectal examination required for the followup of prostate cancer?
Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3.
Kallikrein-kinin system in patients with neoplastic diseases.
Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?
Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma.
Kappa statistics in the screening of malignancy of prostate.
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Kinin receptors are expressed in human astrocytic tumour cells.
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Knowledge of prostate cancer screening among native African urban population in Nigeria.
Laparoscopic pelvic lymph node dissection.
Laparoscopic radical prostatectomy with a remote controlled robot.
Laparoscopic Radical Prostatectomy with a Remote Controlled Robot.
Laparoscopic radical prostatectomy.
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy.
Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Lesion Targeted CT-Guided Transgluteal Prostate Biopsy in Combination With Prebiopsy MRI in Patients Without Rectal Access.
Levels of glandular kallikrein in whole saliva obtained from patients with solid tumors remote from the oral cavity.
Life events, cortisol and levels of prostate specific antigen: A story of synergism.
Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database.
Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.
Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer In Vivo.
Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada.
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis.
Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy.
Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis.
Long-Term Combined Androgen Blockade Alone for Localized Prostate Cancer.
Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.
Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
Low incidence of fatigue after hypofractionated stereotactic body radiation therapy for localized prostate cancer.
Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma.
Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System.
Luminescence energy transfer detection of PSA in red region based on Mn2+-enhanced NaYF4:Yb, Er upconversion nanorods.
Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
Macrocystic ductal adenocarcinoma of prostate: A rare gross appearance of prostate cancer.
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
Magnetic resonance imaging of clinically localized prostatic cancer.
Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007.
Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure.
Management of high risk metastatic prostate cancer: the case for novel therapies.
Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy?
Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.
Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Mass screening for prostate cancer in Korea: a population based study.
Matriptase and its putative role in cancer.
Measurement of weekly prostate specific antigen levels in patients receiving pelvic radiotherapy for nonprostatic malignancies.
Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy.
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Metal-organic gel enhanced fluorescence anisotropy for sensitive detection of prostate specific antigen.
Metastatic carcinoma of the prostate mimicking primary carcinoid tumor of the lung and mediastinum.
Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters.
Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.
MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.
Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis.
Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.
Model predictive control for optimally scheduling intermittent androgen suppression of prostate cancer.
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Molecular pathology of prostate cancer.
Monocyte tissue factor levels in cancer patients.
Monocyte tissue factor levels in patients with urological tumours: an association between tumour presence and progression.
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
Morphometric and clinical studies on 68 consecutive radical prostatectomies.
mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients.
Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.
Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
Multiplex detection platform for tumor markers and glucose in serum based on a microfluidic microparticle array.
Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less.
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
N-cadherin switching occurs in high Gleason grade prostate cancer.
Nanoporous gold film based immunosensor for label-free detection of cancer biomarker.
National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer.
Natural course of localized prostate cancer. a personal view with a review of published papers.
Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
Neighborhood socioeconomic status modifies the association between individual smoking status and PAH-DNA adduct levels in prostate tissue.
Nerve-sparing radical prostatectomy: evaluation of results after 250 patients.
Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination.
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells.
Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
Occult prostate adenocarcinoma with pulmonary metastasis: diagnosis by fine needle aspiration biopsy of the lung and immunohistochemistry.
On-a-chip Biosensing Based on All-Dielectric Nanoresonators.
Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen.
Oral administration of naturally occurring chitosan based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.
Oral testosterone replacement in Korean patients with PADAM.
Origin of carcinomas causing bladder neck obstruction demonstrated by immunoperoxidase localisation of specific antigens.
Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.
Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
p38 MAPK Inhibition Mitigates Hypoxia-Induced AR Signaling in Castration-Resistant Prostate Cancer.
PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores.
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.
Paper-based electrochemical immunoassay for rapid, inexpensive cancer biomarker protein detection.
Papillary adenocarcinoma of the male urethra. Case report and review of the literature.
Papillary cystoadenocarcinoma of the prostate.
Parenchymal brain metastases from adenocarcinoma of prostate.
Participation of older patients with prostate cancer in Medicare eligible trials.
Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone.
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology.
Pathological features of localized prostate cancer in China: a contemporary analysis of radical prostatectomy specimens.
Pathological outcomes in men with prostate cancer who are eligible for active surveillance.
Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
Patient selection and counseling before prostatic arterial embolization.
Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner.
Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors.
Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy.
Patterns of Local Failure following Radiation Therapy for Prostate Cancer.
Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort.
PEG-based autonomous capillary system with integrated microbead array for immunoassay.
Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Percent free PSA as an additional measure in a prostate cancer screen.
Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.
Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy.
Personalized approach to prostate cancer prognosis.
Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.
Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance.
Phyllodes tumor of the prostate: long-term followup study of 23 cases.
Phyllodes tumor of the seminal vesicle: case report and literature review.
Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Plasma sialic acid in patients with prostate cancer.
Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression.
POTENCY, CONTINENCE AND COMPLICATIONS IN 3,477 CONSECUTIVE RADICAL RETROPUBIC PROSTATECTOMIES.
Practice trends in the diagnosis and management of prostate cancer in the United States.
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy.
Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation.
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings.
Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer.
Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.
Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
Prediction of pathological stages before prostatectomy in prostate cancer patients: Analysis of 12 systematic prostate needle biopsy specimens.
Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
Predictors of prostate cancer after initial negative systematic 12 core biopsy.
Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Preoperative nomograms for predicting extracapsular extension in Korean men with localized prostate cancer: a multi-institutional clinicopathologic study.
Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies.
Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer.
Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy.
Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.
Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer.
Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.
Prevalence of abnormal levels of serum tumour markers in elderly people.
Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen.
Prevalence of the use of cancer related self-tests by members of the public: a community survey.
Primary Cribriform Carcinoma of the Eyelid With Neuroendocrine Features: A Case Report.
Primary signet ring cell adenocarcinoma of the prostate treated by radical prostatectomy after preoperative androgen deprivation.
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection.
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Prognostic factors in prostate cancer.
Prognostic Impact of Subclassification of Radical Prostatectomy Positive Margins by Linear Extent and Gleason Grade.
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era.
Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma.
Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma.
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey.
Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage t0 to 4,N1 to 3.M0,D1). European Organization for Research and Treatment of Cancer Genitourinary Group.
Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.
Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels.
Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.
Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race.
Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy.
Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Prostate cancer - Active surveillance as a management option.
Prostate Cancer - What's New?
Prostate Cancer and Its Mimics at Multiparametric Prostate MRI.
Prostate cancer and microfluids.
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml.
Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
Prostate cancer detection in veterans with a history of Agent Orange exposure.
Prostate cancer detection is also relevant in low prostate specific antigen ranges.
Prostate cancer diagnosed by the 5 region biopsy method is significant disease.
Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
Prostate cancer in men using testosterone supplementation.
Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Prostate cancer prevention and finasteride.
Prostate cancer risk assessment program: a 10-year update of cancer detection.
Prostate cancer screening in New Zealand: lessons from the past to shape the future in the light of changing evidence.
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension.
Prostate cancer volume at biopsy predicts clinically significant upgrading.
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.
Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens.
Prostate cancer: relative effects of demographic, clinical, histologic, and MR imaging variables on the accuracy of staging.
Prostate cancer: who to screen, and what the results mean.
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy.
Prostate imaging features that indicate benign or malignant pathology on biopsy.
Prostate size does not predict high grade cancer.
Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.
Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.
Prostate specific antigen as tumor marker: relationship with histologic grading.
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.
Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Prostate specific antigen density in patients with histologically proven prostate carcinoma.
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Prostate specific antigen for early detection of prostate cancer: longitudinal study.
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate.
Prostate specific antigen in the diagnosis and staging of prostate cancer.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
Prostate specific antigen kinetics in the management of prostate cancer.
Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black american men but not in white men: results from a consecutive series of 914 men.
Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera.
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence.
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Prostate-specific antigen: its clinical use and application in screening for prostate cancer.
Prostatic asymmetry as a risk factor for prostatic carcinoma: serial prostate-specific antigen monitoring and cancer detection.
Prostatic cystic epithelial-stromal tumors: a report of 2 new cases.
Prostatic intraepithelial neoplasia and prostate cancer.
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer.
Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.
PSA and other tissue kallikreins for prostate cancer detection.
PSA density (PSAD). Role in patient evaluation and management.
PSA relapse prostate cancer: the importance of tailored therapy.
PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
Quantification of perineural invasion focus after radical prostatectomy could improve predictive power of recurrence.
Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.
Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.
Quantitative, label-free detection of five protein biomarkers using multiplexed arrays of silicon photonic microring resonators.
Race is not a predictor of prostate cancer detection on repeat prostate biopsy.
Racial differences in a prostate cancer screening study.
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.
Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes.
Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view.
Radical perineal prostatectomy: a model for evaluating local response of prostate therapy.
Radical perineal prostatectomy: oncological outcome during a 20-year period.
Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome.
Radical prostatectomy in men less than 50 years old.
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.
Radioisotope guided pelvic lymph node dissection for prostate cancer.
Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
Rapid chemiluminescent sandwich enzyme immunoassay capable of consecutively quantifying multiple tumor markers in a sample.
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.
Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer.
Re: Short Term Outcomes of Prostate Biopsy in Men Tested for Cancer by Prostate Specific Antigen: Prospective Evaluation Within ProtecT Study.
Real-time prostate-specific antigen detection with prostate-specific antigen imprinted capacitive biosensors.
Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.
Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness.
Recombinant human alpha fetoprotein synergistically potentiates the anti-cancer effects of 1'-S-1'-acetoxychavicol acetate when used as a complex against human tumours harbouring AFP-receptors.
Reconnoitring the status of prostate specific antigen and its role in women.
Rectal Invasion by Prostatic Adenocarcinoma That Was Initially Diagnosed in a Rectal Polyp on Colonoscopy.
Recurrent prostate cancer despite undetectable prostate specific antigen.
Relationship between histologic grading and serum prostate specific antigen in prostatic carcinoma.
Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project.
Reliability of volume or age-adjusted prostate specific antigen to improve diagnostic accuracy.
Repeat prostate-specific antigen test before prostate biopsy: a 20% decrease in prostate specific antigen values is associated with a reduced risk of cancer and particularly of high-grade cancer.
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer.
Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications.
Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
Results of compliance with prostate cancer screening guidelines.
Rh2 synergistically enhances Paclitaxel or mitoxantrone in prostate cancer models.
Rising prostate specific antigen after radical prostatectomy: a case based review.
Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test.
Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Risk of suicide in men with low-risk prostate cancer.
Robust, Highly Visible, and Facile Bioconjugation Colloidal Crystal Beads for Bioassay.
Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.
Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer.
Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer.
Rolling circle amplification integrated with suspension bead array for ultrasensitive multiplex immunodetection of tumor markers.
Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice.
Rye Whole Grain and Bran Intake Compared with Refined Wheat Decreases Urinary C-Peptide, Plasma Insulin, and Prostate Specific Antigen in Men with Prostate Cancer.
Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.
Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.
Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours.
Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
Screening and early detection for prostate cancer.
Screening for cancer. Is it useful?
Screening for carcinoma of the prostate: a GP based study.
Screening for familial and hereditary prostate cancer.
Screening for new peptide substrates for the development of albumin binding anticancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy.
Screening for occult nodal metastasis in localized carcinoma of the prostate.
Screening of 5- and 6-Substituted Amiloride Libraries Identifies Dual-uPA/NHE1 Active and Single Target-Selective Inhibitors.
Screening of prostate cancer in males with prostatism.
Secondary signet ring cell carcinoma of prostate.
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization.
Selenium: epidemiology and basic science.
Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction.
Sensitive electrochemical immunosensor for cancer biomarker with signal enhancement based on nitrodopamine-functionalized iron oxide nanoparticles.
Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Serial analysis of gene expression (SAGE) in the rat limbal and central corneal epithelium.
Serial biopsy results in prostate cancer screening study.
Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens.
Serum ceruloplasmin as a marker in prostate cancer.
Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.
Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study.
Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones.
Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.
Serum tumor markers in hemodialysis patients.
Serum tumor markers in patients on dialysis and kidney transplantation.
Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer.
Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens.
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial.
Signet-ring carcinoma of the prostate.
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens.
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.
Simultaneous Detection of Multiple Tumor Markers in Blood by Functional Liquid Crystal Sensors Assisted with Target-Induced Dissociation of Aptamer.
Single Molecule Upconversion-Linked Immunosorbent Assay with Extended Dynamic Range for the Sensitive Detection of Diagnostic Biomarkers.
Single port robotic radical prostatectomy: a systematic review.
Skene's gland adenocarcinoma with intestinal differentiation: A case report and literature review.
Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients.
Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study.
Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups.
Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Socioeconomic variation and prostate specific antigen testing in the community: a United kingdom based population study.
Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy.
Squamous cell carcinoma of the prostate following treatment with an LHRH-agonist: a rare case of transformation of adenocarcinoma of the prostate.
Staging laparoscopic pelvic lymph node dissection: comparison of results with open pelvic lymphadenectomy.
Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
Status of External Quality Assessment on Tumor Markers in China.
Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Stopping screening, when and how?
Storm over screening for prostate specific antigen. Give men facts on prostate cancer.
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour.
Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Subcutaneous Fat Distribution Is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation.
Sulfur inhibits the growth of androgen-independent prostate cancer in vivo.
Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden.
Survival in blacks and whites after treatment for localized prostate cancer.
Susceptibility Loci associations with prostate cancer risk in northern chinese men.
Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma.
Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk.
Systemic radioligand therapy with (177)Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer.
T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report.
Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.
Targeted Prostate Biopsy Gleason Score Heterogeneity and Implications for Risk Stratification.
Targeting kallikrein-related peptidases in prostate cancer.
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
Targeting thapsigargin towards tumors.
Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen.
Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy.
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.
The age-specific reference intervals for tPSA, fPSA, and %fPSA in healthy Han ethnic male.
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men.
The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model.
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.
The association between total prostate specific antigen concentration and prostate specific antigen velocity.
The Chance of Small Interfering RNAs as Eligible Candidates for a Personalized Treatment of Prostate Cancer.
The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration.
The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy.
The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
The correlation of stage and pathology of prostate cancer in Japan.
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
The effect of antibiotics on elevated serum prostate specific antigen in patients with urinary symptoms and negative digital rectal examination: a pilot study.
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.
The effect of pelvic radiation therapy on serum levels of prostate specific antigen.
The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels.
The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
The epidemic of prostate cancer and the medical literature: a causal association?
The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens.
The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate.
The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
The Impact of Clinical Stage on Prostate Cancer Survival Following Radical Prostatectomy.
The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy.
The impact of intra-operative cell salvage during open radical prostatectomy.
The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer.
The Impact of Prostate Cancer Zonal Origin on Pathological Parameters at Radical Prostatectomy and Subsequent Biochemical Failure.
The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.
The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies.
The independent impact of extended pattern biopsy on prostate cancer stage migration.
The influence of age, sex and race on salivary kallikrein levels in human mixed saliva.
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy.
The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
The malignancy index in plasma samples as a prostate cancer biomarker.
The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients.
The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies.
The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
The new human kallikrein gene family: implications in carcinogenesis.
The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy.
The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
The older the better: The characteristic of localized prostate cancer in Chinese men.
The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram.
The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.
The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.
The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer.
The prognostic value of inducible nitric oxide synthase in local prostate cancer.
The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer.
The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
The prostate specific antigen. Its use as a tumor marker for prostate cancer.
The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate.
The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
The relationship between serum prostate specific antigen level and tumor volume persists in the current era.
The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma.
The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: a comparative study.
The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against.
The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.
The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted.
The significance of isoechoic prostatic carcinoma.
The significance of low-grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor.
The significance of monoamine oxidase-A expression in high grade prostate cancer.
The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.
The treatment of prostate cancer: how is failure defined and how can it be minimized?
The use of (68 ) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen.
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
The utility of free to total PSA ratio for detecting prostate cancer in Japanese men with total PSA between 2.1 and 10 ng/ml.
The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma.
The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy.
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study.
Time trends in pathologic features of radical prostatectomy--impact of family history.
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Tissue Biomarkers for Prostate Cancer Radiation Therapy.
Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Touch preparation cytological evaluation of radical prostatectomy specimens.
Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Transformation of prostatic adenocarcinoma to well differentiated neuroendocrine tumor after hormonal treatment.
Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I.
Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.
Transperineal prostate biopsy after abdominoperineal resection.
Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study.
Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor.
Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): a Comparison Between the CaPSURE Data and the NUORG Data.
Tumor detection of 18F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method.
Tumor marker requests in a general teaching Turkish hospital.
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability.
Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.
Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors.
Tumour markers as prognostic aids in prostatic carcinoma.
Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
Tumour markers in prostatic cancer.
Tumour metabolites regulate tissue kallikrein in human umbilical vein endothelial cells.
Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen.
Ultra-sensitive protein detection via Single Molecule Arrays towards early stage cancer monitoring.
Ultrasensitive Detection of Dual Cancer Biomarkers with Integrated CMOS-Compatible Nanowire Arrays.
Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers.
Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer.
Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.
Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.
Urinary PSA level and relative tumor volume after prostate biopsy.
Urinary tissue factor levels in neoplastic diseases.
Urinary tissue factor levels in prostatic carcinoma: a potential marker of metastatic spread?
Use of common seric tumor markers in patients with solid cancers.
Use of quality indicators to evaluate the care of patients with localized prostate carcinoma.
Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer.
Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update.
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samples.
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection.
Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation.
Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy.
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens.
Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.
Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy.
Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis.
Virus encoded circulatory miRNAs for early detection of prostate cancer.
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy.
Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma.
Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells.
Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience.
Watchful waiting and factors predictive of secondary treatment of localized prostate cancer.
Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook.
What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
What should be done to minimize pain without any sexual function deterioration in transrectal prostate biopsy?
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Words of wisdom. Re: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Words of wisdom. Re: Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
Zonal biopsy in the detection of prostate cancer in Japanese men.
Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer.
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
[11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.
[A case of clear cell adenocarcinoma of the female urethra]
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
[A case of prostate cancer presenting as extensive abdominal metastasis].
[A case of prostate cancer that developed following transurethral resection of the prostate: diagnostic efficiency of diffusion-weighted images on magnetic resonance imaging]
[A Case Report : Primary Urothelial Carcinoma of the Prostate Producing Interleukin-6 Detected from a Fever].
[A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential].
[A preliminar mathematical model for patients with a previous negative prostate biopsy]
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
[Adenocarcinoma of the prostate]
[Apoptosis in pathologic prostatic processes]
[Application of angiotensin II receptor blocker in prostate cancer]
[Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer]
[Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers]
[Cancer of the prostate: influence of nutritional factors. A new nutritional approach]
[Changes in tumor markers following cryosurgery of prostate carcinoma]
[Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels]
[Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer]
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
[Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein]
[Clinical studies of stage D2 prostatic cancer]
[Clinical study of prostatic cancer--statistical analysis of 184 cases in the latest 21 years]
[Clinical study of tumor marker in prostatic carcinoma--clinical significance of the prostate specific antigen (PA)]
[Clinical usefulness of the free and total prostate specific antigen ratio in the diagnosis of cancer of the prostate]
[Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations]
[Comparison of tumor markers versus their relative values to prostatic volume in detecting prostate cancer]
[Conventional serum tumor markers in liver cancer. Retrospective analysis of 118 patients].
[Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer]
[Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy]
[Digital rectal examination, transrectal ultrasonography and prostate specific antigen for diagnosis of prostate cancer in clinical urological practice-detection of impalpable cancer]
[Disease relapses after radical radiotherapy of prostate cancer--analysis of prognostic factors]
[Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma]
[Docetaxel for small cell carcinoma of the prostate with a metastatic pelvic tumor : a case report].
[Early detection and follow-up of prostatic carcinoma. Responsibilities of the general practitioner]
[Early detection of prostate cancer: a summary of the past 10 years].
[Effects of anti-gene and antisense therapeutics on human prostate cancer xenograft in nude mice]
[Effects of digital rectal examination on serum prostate specific antigen]
[Establishment of reference intervals of tumor markers in Korean adults]
[Examination of prostate biopsy among Japanese with less than 4.0 ng/ml prostate specific antigen--usefulness of free/total PSA ratio]
[Expression of endocrine-paracrine cells in prostatic carcinoma]
[Giant prostate carcinoma treated effectively with endocrine therapy: case report]
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].
[Laparoscopic pelvic lymph node dissection valuable in the staging of clinically localized prostate carcinoma]
[Laparoscopic pelvic lymphadenectomy in patients with localized prostate cancer]
[Lymphatic involvement predominating and revealing prostatic carcinoma]
[Mass screening for prostate cancer in Nagano]
[Mucinous adenocarcinoma of the prostatic gland. Histochemical and immunohistochemical studies]
[National external quality assessment and comparability of assays for tumor markers measurements]
[Occult cancer in patients with symptomatic benign prostatic hyperplasia]
[Ophthalmoplegia in a patient with prostate cancer and bone metastases]
[Post-treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate]
[Potential of ultrasonography and ultrasonography-guided biopsy in the diagnosis of local recurrence following radical prostatectomy]
[Preliminary data on our laparoscopy experience in urinary pathology]
[Prognosis in stage a prostate cancer]
[Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report]
[Prostate cancer]
[Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml]
[Prostate specific antigen (PSA): impact of a seric marker on the diagnosis and therapeutic management of cancers of the prostate]
[Prostate specific antigen and diagnosis of prostate cancer]
[Prostate specific antigen. Clinical applications of ultrasensitive assay]
[Prostate specific antigen: its proper diagnostic use]
[Prostate-specific antigen as a tumor marker of prostate carcinoma]
[Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia]
[Prostatic carcinoid and neuroendocrine tumors--a case report]
[Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen]
[PSA in early detection of prostate cancer and course of disease]
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
[Recent improvements and results of radical prostatectomy]
[Rectal involvement by prostate carcinoma: a report of three cases]
[Reference values of prostate specific antigen (PSA) in 63926 workers without prostatic symptoms who participated in prostate screening cancer developed by the Ibermutuamur Prevention Society in 2006]
[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients]
[Selective application of tumor markers PSA]
[Sense and nonsense of tumor markers in practice]
[Sensitivity and specificity evaluation of endorectal magnetic resonance imaging and transrectal sonography in the staging of prostate cancer.]
[Significance of the PSA-concentration for the detection of prostate cancer]
[Skip metastasis of prostate cancer: diagnosis and treatment]
[Spermatic cord liposarcoma. Association with prostate cancer. Report of a case and review of literature]
[Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer]
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer]
[The incidence, mortality and risk factors of prostate cancer].
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
[The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group]
[The role of PSA in diagnosis of prostate cancer and its recurrence]
[Transrectal ultrasound examination of the prostate in 100 cases of prostate cancer]
[Treatment of metastatic prostate cancer: certainty and doubts]
[TROUSSEAU'S SYNDROME ACCOMPANIED BY ADVANCED PROSTATE CANCER THAT DEVELOPED ISCHEMIC STROKE; A CASE REPORT].
[Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)]
[Tumor markers of urinary tract carcinoma]
[Use of prostate specific antigen. A review]
[Usefulness of free prostate specific antigen in the detection of prostate cancer]
[Usefulness of prostate specific antigen/gamma-seminoprotein ratio for diagnosis of prostate cancer]
[When should bone scanning be carried out in prostatic cancer?]
Neoplasms, Germ Cell and Embryonal
Human tissue kallikreins and testicular cancer.
Neoplasms, Second Primary
The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Neoplastic Cells, Circulating
Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Prostate cancer and microfluids.
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
[Clinical significance of detecting circulating cancer cells in patients with solid malignancies]
Nervous System Diseases
Treatment options for benign prostatic hyperplasia in older men.
Neuroblastoma
Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays.
Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model.
Neuroendocrine Tumors
Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Pure small cell carcinoma of the prostate.
Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Neuroinflammatory Diseases
Human Urinary Kallidinogenase Reduces Lipopolysaccharide-Induced Neuroinflammation and Oxidative Stress in BV-2 Cells.
Newcastle Disease
Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells.
Non-alcoholic Fatty Liver Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Obesity
Age and Obesity Promote Methylation and Suppression of 5?-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Association of Body Mass Index With Prostate Cancer Biochemical Failure.
Association of obesity with prostate specific antigen and prostate specific antigen velocity in healthy young men.
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population.
Health risk behaviors and prostate specific antigen awareness among men in California.
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database.
Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy.
Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
Obesity and prostate cancer.
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Prostate specific antigen mass ratio potential as a prostate cancer screening tool.
Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
Renal functional reserve in obesity hypertension.
Should Prostate Specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.
The inverse relationship between prostate specific antigen (PSA) and obesity
The inverse relationship between prostate specific antigen (PSA) and obesity.
The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
[Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen].
Obesity, Abdominal
Effect of central obesity on prostate specific antigen measured by computerized tomography: related markers and prostate volume.
Oligospermia
Evaluation of three rapid detection methods for the forensic identification of seminal fluid in rape cases.
Osteoarthritis
A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Osteoporosis
Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation.
Otitis Media
A top 5 list for French general practice.
Otitis Media with Effusion
A top 5 list for French general practice.
Ovarian Neoplasms
A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.
A novel protease homolog differentially expressed in breast and ovarian cancer.
Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site.
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.
Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.
Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Arm.
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
Prostate specific antigen (PSA) in breast and ovarian cancer.
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context.
Overweight
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.
Pancreatic Neoplasms
Combining diagnostic test results to increase accuracy.
Urinary kallikrein excretion in chronic pancreatic diseases.
Pancreatitis
Expression and characterization of human tissue kallikrein variants.
Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats.
Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats.
Kallikrein, kininogen and kinins in control of blood pressure.
Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.
Role of the kallikrein-kinin system in human pancreatitis.
Studies on the release of tissue kallikrein in experimental pancreatitis in the pig.
Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.
Urinary kallikrein excretion in chronic pancreatic diseases.
[Enzyme liberation and activation of the kallikrein-kinin system in experimental pancreatitis. Studies of portal vein blood, pancreatic lymph and peritoneal effusion]
Pancreatitis, Acute Necrotizing
Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.
Pancytopenia
[Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report].
Paralysis
Bilateral third and unilateral sixth nerve palsies as early presenting signs of metastatic prostatic carcinoma.
Parkinson Disease
Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Parotitis
Effect of radioactive iodine therapy on parotid gland function.
New concepts in the treatment of chronic recurrent parotitis.
[Glandular kallikrein in chronic recurrent parotitis]
[Treatment of chronic recurring parotitis with the protease inhibitor aprotinin (trasylol)]
Pemphigus
Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem).
Periodontal Diseases
Blood flow, collagen components of oral tissue and salivary kallikrein in young to senescent, germfree and conventional rats. A study on the etiologic factors of periodontal disease.
Salivary kallikrein and kininase activities in periodontal diseases.
[Role of salivary kallikrein in the pathogenesis of periodontosis]
Periodontal Pocket
[Experimental periodontitis in rats]
Peripheral Arterial Disease
Comparative effectiveness in urology: a state of the art review utilizing a systematic approach.
Pheochromocytoma
Autopsy case of prostate cancer with multiple endocrine neoplasia 2A.
Pituitary Diseases
INITIAL SYMPTOMATIC PITUITARY METASTASIS IN A PATIENT WITH PROSTATE FOAMY GLAND CARCINOMA: TAILORING SAFE AND EFFECTIVE THERAPY.
Pituitary Neoplasms
Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours.
Decreasing prostate specific antigen value leading to the diagnosis of a pituitary adenoma.
Elevated glandular kallikrein in estrogen-induced pituitary tumors.
Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin.
Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
plasma kallikrein deficiency
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.
Pleural Effusion, Malignant
[Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer]
Pneumonia
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Granzyme K activates protease-activated receptor-1.
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Polycystic Ovary Syndrome
A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome.
Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome - a new insight.
Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome.
Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination.
The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs).
Polycythemia
[Hormone replacement Up-to-date. Clinical practice of androgen replacement therapy]
Pre-Eclampsia
Localisation of tissue kallikrein in the kidney of black African women with early onset pre-eclampsia: a pilot study.
Plasma concentrations of tissue kallikrein in normal and preeclamptic pregnancies.
Tissue kallikrein activity in pregnancy.
Urinary tissue kallikrein excretion in black African women with severe pre-eclampsia.
Proctitis
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Prolactinoma
Bioregulatory role of the kallikrein-kinin system in the normal pituitary gland and its tumours.
Characterization of a tissue kallikrein in human prolactin-secreting adenomas.
Tissue kallikrein and the effect of bromocriptine in human prolactin and growth hormone-secreting pituitary adenomas.
Tissue kallikrein is associated with prolactin-secreting cells within human growth hormone-secreting adenomas.
Prostatic Diseases
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Case report. Two contrasting radiological presentations of prostatic adenocarcinoma in the jaws.
Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Enzymatically active prostate-specific antigen promotes growth of human prostate cancers.
Expression of prostate specific antigen in male breast cancer.
Gamma-seminoprotein--a new tumour marker in prostatic cancer? Results of a pilot study.
Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
Kappa statistics in the screening of malignancy of prostate.
Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts.
New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease.
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
Prostate-specific antigen density: a new prognostic indicator for prostate cancer.
Psychological Distress and Prostate Specific Antigen Levels in Men with and without Prostate Cancer.
Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men.
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients.
The impact of educational sessions provided on prostate cancer, and its screening tests on the knowledge level, and participation behavior of the individuals in questionnaire surveys.
The lady with raised prostate specific antigen: do we need to worry?
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
[A mass screening of the prostatic diseases and serum prostate specific antigen]
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]
[Influence of age on serum prostate specific antigen concentration]
[Prostate-specific antigen. Interpretation of the results in relation to the sampling method]
[Screening for prostatic diseases in one-day total health check-up by using prostate specific antigen, international prostate symptom score and QOL index]
Prostatic Hyperplasia
A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening.
A rational approach to benign prostatic hyperplasia evaluation: recent advances.
A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.
A study of prostane in the treatment of benign prostatic hyperplasia.
Adaptive spaced education improves learning efficiency: a randomized controlled trial.
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
An evaluation of prostate specific antigen in prostatic cancer.
Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.
Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Bleeding and activation of coagulation during and after transurethral prostatectomy: importance of the acute-phase response and prostate specific antigen?
Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Changing trends in the management of prostatic disease in a single private practice: a 5-year followup.
Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men.
Clinical use of prostate specific antigen in patients with prostate cancer.
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue.
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia.
Determinants of ejaculatory dysfunction in a community-based longitudinal study.
Determination of transition zone volume by transrectal ultrasound in patients with clinically benign prostatic hyperplasia: agreement with enucleated prostate adenoma weight.
Development and initial evaluation of a novel urology curriculum for medical students.
Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education.
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy.
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia.
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.
Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy.
Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
Elevation of prostate specific antigen in cardiac surgery with extracorporeal cardiopulmonary circulation.
Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.
Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer.
Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.
Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Expression of human prostatic acid phosphatase and prostate specific antigen genes in neoplastic and benign tissues.
First clinical results with Enzymun-Test for free PSA.
Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.
GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition.
Holmium laser enucleation of the prostate--outcomes independent of prostate size?
Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein.
IgG4-Related Autoimmune Prostatitis: Is It an Unusual or Underdiagnosed Manifestation of IgG4-Related Disease?
Impact of Prostate Specific Antigen and Testosterone Hormone Levels in Patients of Benign Prostatic Hyperplasia in Khartoum State-Sudan.
Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value.
Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value.
Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate specific antigen.
Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial.
Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia?
Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment.
Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
MOLECULAR MARKERS ASSOCIATED WITH PROSTATE CANCER: 3-NITROTYROSINE AND GENETIC AND PROTEIC EXPRESSION OF MN-SUPEROXIDE DISMUTASA (MN-SOD).
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis.
Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.
Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
Prevention of benign prostatic hyperplasia disease.
Prospective, Randomized, Double-Blind, Vehicle Controlled, Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia.
Prostate cancer detection in candidates for open prostatectomy.
Prostate cancer prevention and finasteride.
Prostate specific antigen and benign prostatic hyperplasia.
Prostate specific antigen and relative prostate weight data on effect of Tetracarpidium conophorum leaf extract on testosterone-induced benign prostatic hyperplasia.
Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.
Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
Prostate specific antigen in the expressed prostatic fluid of men with benign prostatic hyperplasia and prostate carcinoma.
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Prostate specific antigen measurements after minimally invasive surgery of the prostate in men with benign prostatic hypertrophy.
Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry.
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Relationship among lymphocytes, free/total prostate specific antigen, lower urinary tract symptoms and prostatic inflammation in benign prostatic hyperplasia patients.
Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperplasia and advanced prostatic carcinoma.
Relationship between prostate specific antigen, prostate volume and age in the benign prostate.
Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia.
Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia.
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.
Serum prostate specific antigen levels during hyperthermia treatment of benign prostatic hyperplasia.
Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml.
Symptom scores, watchful waiting and prostate specific antigen levels in benign prostatic hyperplasia.
The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
The effect of finasteride on prostate specific antigen: review of available data.
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
The effects of ejaculation on serum prostate specific antigen.
The effects of extracorporeal cardiopulmonary circulation on serum total and free prostate specific antigen levels.
The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride.
The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia.
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.
The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Trends in diagnosis of stage T1a-b prostate cancer.
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL.
Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men.
Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group.
Validity of digital rectal examination in the era of prostate specific antigen.
Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?
[Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
[Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen].
[Benign prostatic hypertrophy with high levels of gamma-seminoprotein (gamma-Sm), prostate specific antigen: report of two cases]
[Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
[Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer]
[Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer]
[Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer]
[Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia]
[Prostate carcinoma: prostate-specific antigen--and then what?]
[Prostate specific antigen in patients with prostatic cancer--clinical usefulness of its measurement with sensitive enzyme immunoassay, TOSOH II PA assay]
[Prostate-specific antigen. The role in the prostate cancer diagnosis].
[Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer]
[Purification and determination of human prostate specific antigen in the serum]
[Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia]
[Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer]
[Significance of various examination methods in the management of prostatic cancer]
[The significance of free-type PSA and complex-type PSA in patients with prostatic carcinoma--the characteristics of ACS-PSA method compared with that of Delfia- and Eiken-PSA method]
[Two cases of mucinous adenocarcinoma of the prostate]
[Validity of digital rectal examination of prostate specific antigen]
[Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia]
[Value of PSA/gamma-Sm ratio (P/S ratio) for diagnosis of prostate cancer in patients with urinary retention]
Prostatic Intraepithelial Neoplasia
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.
A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
Chemoprevention of prostate cancer with nutrients and supplements.
Chemoprevention of prostate cancer: agents and study designs.
Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?
Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer.
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study.
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.
Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma.
Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen.
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race.
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
Prostatic intraepithelial neoplasia and prostate cancer.
Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer.
Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk.
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens.
The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies.
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
Weaker ERG expression in patients with ERG-positive prostate cancer is associated with advanced disease and weaker androgen receptor expression: An Indian outlook.
Prostatic Neoplasms
"Mix-to-Go" Silver Colloidal Strategy for Prostate Cancer Molecular Profiling and Risk Prediction.
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer.
'Prostate Cancer Risk Calculator' mobile applications (Apps): a systematic review and scoring using the validated user version of the Mobile Application Rating Scale (uMARS).
(18)F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer.
(68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer.
(68)Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review.
(99m)Tc-MDP uptake in SPECT/CT by a bladder hernia simulating inguinal metastasis: A case report.
111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
11C-choline PET/CT predicts survival in prostate cancer patients with PSA?
13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
18F-choline PET/mpMRI for Detection of Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis.
18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies.
2-Methoxyestradiol, a promising anticancer agent.
25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate.
25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy.
25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology.
25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series.
2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer.
3D label-free prostate specific antigen (PSA) immunosensor based on graphene-gold composites.
3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray.
4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor.
5?-Reductase Inhibition Coupled with Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy.
68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.
A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy.
A case of Sister Mary Joseph's nodule from prostatic cancer.
A case study: ductal adenocarcinoma of the prostate.
A centralized comparison of radical perineal and retropubic prostatectomy specimens: is there a difference according to the surgical approach?
A chemiluminescent dual-aptasensor capable of simultaneously quantifying prostate specific antigen and vascular endothelial growth factor.
A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen.
A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: A cluster RCT.
A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort.
A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models.
A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995.
A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer.
A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.
A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience.
A deep imputation and inference framework for estimating personalized and race-specific causal effects of genomic alterations on PSA.
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
A dual-round signal amplification strategy for colorimetric/photoacoustic/fluorescence triple read-out detection of prostate specific antigen.
A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
A Four-kallikrein Panel and ?-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Prostate Cancer Screening, Rotterdam.
A framework for the identification of men at increased risk for prostate cancer.
A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates.
A guideline to clinical utility of prostate specific antigen.
A label-free fluorescent aptasensor based on HCR and G-quadruplex DNAzymes for the detection of prostate-specific antigen.
A large, benign prostatic cyst presented with an extremely high serum prostate-specific antigen level.
A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations.
A long follow-up on prostate specific antigen density and prostate biopsy.
A mechanistic insight into the anti-metastatic role of the prostate specific antigen.
A miniature chip for protein detection based on magnetic relaxation switches.
A molecularly imprinted electrochemical nanobiosensor for prostate specific antigen determination.
A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
A Multi-Institutional Prospective Trial in the Veterans Affairs Health System Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men.
A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.
A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting.
A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.
A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.
A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.
A new luciferase reporter gene assay for the detection of androgenic and antiandrogenic effects based on a human prostate specific antigen promoter and PC3/AR human prostate cancer cells.
A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
A Non-Enzymatic and Label-Free Fluorescence Bioassay for Ultrasensitive Detection of PSA.
A novel aptamer-functionalized MoS2 nanosheet fluorescent biosensor for sensitive detection of prostate specific antigen.
A novel fluorescent assay based on DNAzyme-assisted detection of prostate specific antigen for signal amplification.
A Novel Lily-of-the-Valley Fragrance Contrast Agent for Magnetic Resonance and Fluorescence Imaging of Prostate Cancer Cells.
A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer.
A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers.
A Parallel Randomized Clinical Trial Examining the Return of Urinary Continence after Robot-Assisted Radical Prostatectomy with or without a Small Intestinal Submucosa Bladder Neck Sling.
A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer.
A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate.
A pilot study of the association of manganese superoxide dismutase and glutathione peroxidase 1 single gene polymorphisms with prostate cancer and serum prostate specific antigen levels.
A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening.
A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml.
A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate.
A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
A prospective, randomized pilot trial of acupuncture of the kidney-bladder distinct meridian for lower urinary tract symptoms.
A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
A quantitative analysis of the costs and benefits of prostate cancer screening.
A randomised controlled trial of the effects of a web-based PSA decision aid, Prosdex. Protocol.
A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk.
A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
A robust electrochemical immunosensor based on hydroxyl pillar[5]arene@AuNPs@g-C3N4 hybrid nanomaterial for ultrasensitive detection of prostate specific antigen.
A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.
A simple and general change-point identifier.
A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity.
A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition.
A technique of bladder neck closure combining prostatectomy and intestinal interposition for unsalvageable urethral disease.
A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
A whole of population-based series of radical prostatectomy in Victoria, 1995 to 2000.
Abdominal Mass After Robotic Assisted Laparoscopic Prostatectomy: Spigelian Type Trocar Hernia.
Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
Abnormal prostatic cells in ejaculates from men with prostatic cancer--a preliminary report.
Abnormal PSA tests--delays in referral.
Accuracy of a new echographic method (RULES, radiofrequency ultrasonic local estimators) in prostate cancer diagnosis.
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer.
Active surveillance for prostate cancer: trials and tribulations.
Activin A Enhances Prostate Cancer Cell Migration via Activation of Androgen Receptor and Is Overexpressed in Metastatic Prostate Cancer.
Actual Contribution of Free to Total PSA Ratio in Prostate Diseases Differentiation.
Adaptive spaced education improves learning efficiency: a randomized controlled trial.
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core.
African-American men and their reflections and thoughts on prostate cancer.
African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance.
African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Age-Related Prostate Specific Antigen Reference Ranges in Healthy Northern Iranian Men.
Age-specific Serum Prostate Specific Antigen Ranges Among Apparently Healthy Nigerian Men Without Clinical Evidence of Prostate Cancer.
Aggressive Variants of Castration Resistant Prostate Cancer.
alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein.
Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia.
American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen.
Amperometric biosensors for detection of the prostate cancer marker (PSA).
An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level.
An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene.
An aptamer based resonance light scattering assay of prostate specific antigen.
An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
An evaluation of five tests to diagnose prostate cancer.
An evaluation of prostate specific antigen in prostatic cancer.
An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a nigerian teaching hospital.
An examination of variations in the uptake of prostate cancer screening within and between the countries of the EU-27.
An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer.
An update of the Gleason grading system.
An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer.
Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
Androgen ablation in addition to radiation therapy for prostate cancer: is there true benefit?
Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices.
Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer.
ANNALS EXPRESS: Frequency of KLK3 gene deletions in the general population.
Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma.
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer.
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Antiandrogenic activity of extracts of diesel exhaust particles emitted from diesel-engine truck under different engine loads and speeds.
Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer.
Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer.
Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells.
Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review.
Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer.
Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
Artificial neural network model to predict biochemical failure after radical prostatectomy.
Assay for prostate specific antigen (PSA): problems and possible solutions.
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Assessing individual risk for prostate cancer.
Assessing prostate cancer growth with mRNA of spermine metabolic enzymes.
Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control.
Assessing uncertainty in microsimulation modelling with application to cancer screening interventions.
Assessment of a new point-of-care system for detection of prostate specific antigen.
Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males.
Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.
Association of AR-V7 and prostate specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer.
Association of Body Mass Index With Prostate Cancer Biochemical Failure.
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Association of ferritin with prostate cancer.
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
ASSOCIATION OF HEMOSPERMIA WITH PROSTATE CANCER.
Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.
Association of schistosomiasis and risk of prostate cancer development in residents of Murehwa rural community, Zimbabwe.
Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.
Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.
Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.
Associations between the expressions of MiR-135 and MiR-92a and pathogenesis of prostate cancer and analysis of their clinical significance.
Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case-control study (the ProtecT study).
Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
Autoantibodies to prostasomes as new markers for prostate cancer.
Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
Automated 3D-printed unibody immunoarray for chemiluminescence detection of cancer biomarker proteins.
Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.
Being on active surveillance: the patient perspective.
Beyond PSA: The Role of Prostate Health Index (phi).
Bias correction to secondary trait analysis with case-control design.
Bioassays based on molecular nanomechanics.
Biochemical characterization of human tissue kallikrein 15 and examination of its potential role in cancer.
Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations.
Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.
Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer.
Biomarkers for prostate cancer detection.
Biomarkers for prostate cancer.
Biomarkers identified for prostate cancer patients through genome-scale screening.
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.
Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006-2013.
Bone scan findings in a North African ethnic group and relation to PSA level and Gleason score of the biopsy.
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.
Brief report: Impact of healthcare quality on prostate specific antigen screening for the early detection of prostate cancer.
Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital.
Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea.
Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml.
Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?
Can microfocal prostate cancer be regarded as low-risk prostate cancer?
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy?
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial.
Cancer chemoprevention by pomegranate: laboratory and clinical evidence.
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
Cancer screening for the primary care physician.
Cancer screening in Australia: future directions in melanoma, Lynch syndrome, and liver, lung and prostate cancers.
Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Cancer-Cells on Chip for Label-Free Detection of Secreted Molecules.
Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
Carbon-11-acetate positron emission tomography (PET), versus fluorine- 18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of more than 1 to 3ng/mL.
Case report of metastatic prostate cancer masquerading as squamous cell carcinoma on the tip of the penis.
CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.
cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes.
Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis.
Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis.
Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience.
Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation.
Changes in Serum PSA During Normal Menstrual Cycle.
Characterisation of the main PSA glycoforms in aggressive prostate cancer.
Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
Characterization of monoclonal antibodies against prostate specific antigen produced by genetic immunization.
Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC-MS/MS.
Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors.
Chemotherapy in the treatment of prostate cancer--is there a role?
Choline PET/CT for prostate cancer: Main clinical applications.
Circulating biomarkers for prostate cancer.
Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection.
Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer.
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.
Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection.
Clarifying the PSA grey zone: The management of patients with a borderline PSA.
Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood.
Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians.
Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation.
Clinical and imaging tools in the early diagnosis of prostate cancer, a review.
Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer.
Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer.
Clinical diagnosis of prostate cancer.
Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.
Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer.
Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.
Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate.
Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.
Clinical significance of prostate specific antigen for early stage prostate cancer detection.
Clinical trials of immunotherapy for advanced prostate cancer.
Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.
Clinical use of prostate specific antigen in patients with prostate cancer.
Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5alpha-Reductase Inhibitor Dutasteride.
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.
Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer.
Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.
Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancer.
Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: the usefulness of complexed prostate specific antigen adjusted for transition zone volume.
Clinical value of transrectal ultrasound-guided puncture biopsy combined with serum prostate specific antigen level in prostate cancer.
Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer.
Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml.
Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan.
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.
Co-registration of MRI and ultrasound: accuracy of targeting based on radiology-pathology correlation.
Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Colocalization of immunoglobulin binding factor and prostate specific antigen in human prostate gland.
Color Doppler sonography of the prostate.
Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer Urinary Samples via Recombinase Polymerase Amplification.
Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling.
Combination of PI-RADS score and PSA density predicts biopsy outcome in biopsy naïve patients.
Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy of Gleason 9-10 Prostate Cancer.
Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure.
Combined tests of prostate specific antigen and testosterone will improve diagnosis and monitoring the progression of prostate cancer.
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Common cancers--genetics, origin, prevention, screening: Parts I and II.
Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer.
Comparative effectiveness in urology: a state of the art review utilizing a systematic approach.
Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Comparative study of alkaline phosphatase and prostate specific antigen in prostate cancer.
Comparative Study of Blood-Based Biomarkers, ?2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors.
Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.
Comparing Revo-i and da Vinci in Retzius-sparing robot-assisted radical prostatectomy: a preliminary propensity score analysis of outcomes.
Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen?
Comparison of 3 investigational assays for the free form of prostate specific antigen.
Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer.
Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer.
Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score.
Comparison of different serum prostate specific antigen measures for early prostate cancer detection.
Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer.
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
Comparison of methods for calculating prostate specific antigen velocity.
Comparison of methods for prediction of prostate cancer in Turkish men with PSA levels of 0-10 ng/mL.
Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications.
Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Comparison of serum uric acid levels between prostate cancer patients and a control group.
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men.
Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
Complementary and alternative therapies in prostate cancer.
Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Complexed prostate specific antigen: better test in the diagnosis of prostate cancer for the clinically relevant 2.5-4 ng/ml total PSA range.
Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination.
Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Contemporary trends in low risk prostate cancer: risk assessment and treatment.
Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.
Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer.
Control of prostate cancer by transrectal HIFU in 227 patients.
Controversies in prostate cancer screening.
Correlation between bone metabolic markers and bone scan in prostatic cancer.
Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans?
Correlation between Prostate Imaging Reporting and Data System Version 2, Prostate-Specific Antigen Levels, and Local Staging in Biopsy-Proven Carcinoma Prostate: A Retrospective Study.
Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.
Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration.
Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men.
Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease.
Correlation of serum prostate specific antigen and semi quantitative tissue RT-PCR from prostate cancer samples.
Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.
Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Could the sextant prostate biopsy be replaced by transurethral resection?
Coumarins from campylotropis hirtella (FRANCH.) SCHINDL. and their inhibitory activity on prostate specific antigen secreted from LNCaP cells.
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings.
Critical-laboratoristic correlation of the diagnostic importance of prostate specific antigen compared with prostatic acid phosphatase and carcinoembryonic antigen in the prostatic cancer.
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP).
Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.
Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results.
Cultural sensitivity and informed decision making about prostate cancer screening.
Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer.
Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists.
Current perspectives on the Gleason grading of prostate cancer.
Current treatment of non-metastatic castration-refractory prostate cancer.
Cut off value of time to prostate specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.
Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study.
Cytokine variations in patients with hormone treated prostate cancer.
Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.
De novo muscle invasive bladder cancer: is there a change in trend?
Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families.
Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision.
Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance.
Defining recurrence after radiation for prostate cancer.
Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
Demographic, Social Support, and Community Differences in Predictors of African-American and White Men Receiving Prostate Cancer Screening in the United States.
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Design of the Prostate Cancer Prevention Trial (PCPT).
Design, synthesis and biological evaluation of thiohydantoin derivatives as novel anti-prostate cancer agents.
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target.
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays.
Detection of cancer biomarkers in serum using a hybrid mechanical and optoplasmonic nanosensor.
Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
Detection of early stage prostate cancer by using a simple carbon nanotube@paper biosensor.
Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.
Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.
Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein.
Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.
Detection of Prostate Cancer in an Ethnically Diverse, Disadvantaged Population With Multiple Prostate Specific Antigen Measurements Before Biopsy.
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels.
Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
Detection of prostate cancer with 11C-methionine positron emission tomography.
Detection of prostate specific antigen based on electrocatalytic platinum nanoparticles conjugated to a recombinant scFv antibody.
Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation.
Detection of prostate specific antigen messenger RNA from pelvic lymph node in prostate cancer.
Detection of prostate specific antigen with nanomechanical resonators.
Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography.
Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology.
Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study.
Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era.
Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era.
Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device.
Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection.
Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Development and Evaluation of an Immunoglobulin Y-Based ELISA for Measuring Prostate Specific Antigen in Human Serum.
Development and external validation of an extended repeat biopsy nomogram.
Development and initial evaluation of a novel urology curriculum for medical students.
Development and validation of health beliefs model scale for prostate cancer screenings (HBM-PCS): Evidence from exploratory and confirmatory factor analyses.
Development of a Listeria monocytogenes based vaccine against prostate cancer.
Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.
Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids.
Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.
Development of glycan specific lectin based immunoassay for detection of prostate specific antigen.
Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Development of validated instrument to measure medical student learning in clinical urology: a step toward evidence based education.
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
Diagnosing prostate cancer - what GPs need to know.
Diagnosis of malignant ascites in prostate cancer by measurement of prostate specific antigen.
Diagnosis of prostate cancer with needle biopsy: should all cases be biopsied before treatment?
Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
Diagnosis, management and screening of early localised prostate cancer.
Diagnostic accuracy of [-2]proPSA versus Gleason score and Prostate Health Index versus Gleason score for the determination of aggressive prostate cancer: a systematic review.
Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.
Diagnostic potential of serum proteomic patterns in prostate cancer.
Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer.
Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer.
Diagnostic test accuracy study of
Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate.
Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL.
Dielectrophoretic label-free immunoassay for rare-analyte quantification in biological samples.
Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence.
Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study.
Dietary phosphorus intake and serum prostate-specific antigen in non-prostate cancer American adults: A secondary analysis of the National Health and Nutrition Examination Survey (NHANES), 2003-2010.
Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA.
Differences in prostate cancer detection rates according to the level of glomerular filtration rate in patients with prostate specific antigen levels of 4.0-10.0 ng/ml.
Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role.
Differential Glycosylation of Cellular Prostate Specific Antigen and the Regulatory Mechanism of Its Secretion.
Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy.
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less.
Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected population.
Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
Discovering subpopulation structure with latent class mixed models.
Discovery and validation of urinary biomarkers for prostate cancer.
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy.
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists.
Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level.
Distinct urinary glycoprotein signatures in prostate cancer patients.
Distribution and secretory pathways of prostate specific antigen, alpha1-antichymotrypsin and prostate secretory granules in prostate cancers.
Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.
DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
DNA Nanoswitch Barcodes for Multiplexed Biomarker Profiling.
DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer.
Do anxiety and distress increase during active surveillance for low risk prostate cancer?
Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 Prostate Cancer?
Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?
Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
Does plasma thiol and disulphide be a new marker for prostate cancer in prostate-specific antigen level between 10 and 20?ng/ml?
Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature.
Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging.
Does prostate specific antigen density correlates with aggressiveness of the prostate cancer?
Does site-specific labelling and individual processing of sextant biopsies improve the accuracy of prostate biopsy in predicting pathological stage in patients with T1c prostate cancer?
Does transrectal ultrasound guided eight-core prostate biopsy improve cancer detection rates in patients with prostate-specific antigen levels of 4.1-10 ng/mL?
Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates.
Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells.
Downward trend in prostate cancer mortality in Quebec and Canada.
DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study.
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
Dual electrochemical genosensor for early diagnosis of prostate cancer through lncRNAs detection.
Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study.
Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan.
Early detection of prostate cancer: evaluating the diagnostic performance of prostate specific antigen by comparing with histological technique among africans.
Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen.
Early Diagnosis and Staging.
Early diagnosis and surgical management of prostate cancer.
Early identification of individuals with prostate cancer in negative biopsies.
Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET/CT.
Early onset prostate cancer: predictors of clinical grade.
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.
Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer.
Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence.
Economic evaluation of prostate cancer screening test as a National Cancer Screening Program in South Korea.
Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong.
Editor's Comment.
Effect of body mass index and waist circumference on prostate specific antigen and prostate volume in a generally healthy Korean population.
Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels.
Effect of ejaculation on serum prostate specific antigen level in screening and non-screening population.
Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.
Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.
Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen.
Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
Effectiveness of the Combined Evaluation of KLK3 Genetics and Free-to-Total Prostate Specific Antigen Ratio for Prostate Cancer Diagnosis.
Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients.
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies.
Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells.
Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
Effects of the MTHFR C677T Polymorphism on Prostate Specific Antigen and Prostate Cancer.
Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma.
Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
Efficacy of brachytherapy combined with endocrine therapy and external beam radiotherapy in the treatment of intermediate and high-risk localized prostate cancer.
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore.
Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer.
Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: A single center study.
Electrical properties of prostatic tissues: I. Single frequency admittivity properties.
Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar, India.
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Elevation of the serum total and free prostate specific antigen levels after stent implantation in patients with coronary artery disease.
Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
Embryonal carcinoma of the testis associated with prostate cancer in a 72-year-old man.
Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Emerging impact of quercetin in the treatment of prostate cancer.
Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis.
Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.
Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers.
Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers.
Energy Dispersive X-Ray Fluorescence Zn/Fe Ratiometric Determination of Zinc Levels in Expressed Prostatic Fluid: A Direct, Non-Invasive and Highly Accurate Screening for Prostate Cancer.
Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer.
Enhancing PSA performance in the diagnosis of prostate cancer.
Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro.
Environmental Exposure to Trace Elements and Prostate Cancer in Three New Zealand Ethnic Groups.
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities.
Enzyme-free sandwich-type electrochemical immunosensor for highly sensitive prostate specific antigen based on conjugation of quantum dots and antibody on surface of modified glassy carbon electrode with core-shell magnetic metal-organic frameworks.
Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean.
Epidemiology, Staging and Management of Prostate Cancer.
Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.
Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.
Epitope mapping of human prostate specific antigen and glandular kallikrein expressed in insect cells.
Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.
ERSPC, PLCO Studies and Critique of Cochrane Review 2013.
Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study.
Establishment of a Urological Surgery Quality Collaborative.
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.
Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy.
Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models.
Estimation of Time Trends of Incidence of Prostate Cancer -an Indian Scenario.
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Ethical issues for cancer screening.
Ethical issues for cancer screenings. Five countries--four types of cancer.
Evaluating multiple diagnostic tests with partial verification.
Evaluating the predictiveness of a continuous marker.
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
Evaluation of a new serum testing method for detection of prostate cancer.
Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma.
Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening.
Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Evaluation of Prostate Needle Biopsies.
Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.
Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.
Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer.
Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer.
Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer.
Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker.
Evaluation of the BioSign PSA membrane test for the identification of semen stains in forensic casework.
Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer.
Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer.
Evaluation ofalpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Evidence for the existence of an organ specific, androgen-independent pathway of progression in patients with metastatic prostate cancer.
Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
Experiences of Uncertainty in Men With an Elevated PSA.
Exploring Prostate Cancer Literacy and Family Cancer Awareness in College Students: Getting Ahead of the Curve in Cancer Education.
Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Expression of E-cadherin in primary prostate cancer: correlation with clinical features.
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Expression of p21(waf1/cip1), p27 (kip1), p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer.
Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
Expression of the multidrug resistance gene in human prostate cancer.
Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis.
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
Extensive serum cytokine analysis in patients with prostate cancer.
Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
Factors affecting prostate cancer screening behaviour in a discrete population of doctors at the university hospital of the west indies, Jamaica.
Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.
Factors influencing prostate cancer screening decisions among African American men.
Factors Predicting Prostate Specific Antigen Failure Following Radical Prostatectomy: Experience with 961 Patients.
Factors predicting prostate specific antigen testing among first-degree relatives of prostate cancer patients.
Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.
Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence.
Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
False positive values of PAP and PSA in complicated and non-complicated benign prostatic hypertrophy.
Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma.
Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer.
Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques.
Feasibility study of an EHR-integrated mobile shared decision making application.
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities.
Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Finasteride-its impact on sexual function and prostate cancer.
Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
First clinical results with Enzymun-Test for free PSA.
Five-alpha-reductase Inhibitors for prostate cancer prevention.
Fluciclovine, Anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid: A Novel Radiotracer for Meningioma.
Fluorescent immunosensor based on CuS nanoparticles for sensitive detection of cancer biomarker.
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Focal therapy for prostate cancer: opportunities and uncertainties.
Follow-up costs after external radiation for low risk prostate cancer.
Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.
FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
Fractionated perineal high-dose-rate temporary brachytherapy combined with external beam radiation in the treatment of localized prostate cancer: is lymph node sampling necessary?
Free / total prostate specific antigen ratio for prostate cancer detection: a prospective blind study.
Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Free and total human glandular kallikrein 2 in patients with prostate cancer.
Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.
Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer.
Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer.
Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.
Full-length antibodies versus single-chain antibody fragments for a selective impedimetric lectin-based glycoprofiling of prostate specific antigen.
Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy.
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
Genetic counseling for prostate cancer risk.
Genetic variants in the distal enhancer region of the PSA gene and their implication in the occurrence of advanced prostate cancer.
Genetic variants in xenobiotic detoxification enzymes, antioxidant defenses and hormonal pathways as biomarkers of susceptibility to prostate cancer.
Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.
GEOGRAPHIC VARIATION ACROSS VETERANS AFFAIRS MEDICAL CENTERS IN THE TREATMENT OF EARLY STAGE PROSTATE CANCER.
Gleason 6 Prostate Cancer: Translating Biology into Population Health.
Glycoproteomics: identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC-MS/MS.
Glycosylation of prostate specific antigen and its potential diagnostic applications.
Glycotyping of prostate specific antigen.
GNRH-agonist or antagonist in the treatment of prostate cancer: a comparision based on oncological results.
GPRC6A regulates prostate cancer progression.
Granulomatous prostatitis mimicking prostate cancer in a patient with psoriatic arthritis: a case report.
Graphene nanocomposites modified electrochemical aptamer sensor for rapid and highly sensitive detection of prostate specific antigen.
GREB1 tissue expression is associated with organ-confined prostate cancer.
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?
Has ultrasonography a role in screening for prostatic cancer?
Health risk behaviors and prostate specific antigen awareness among men in California.
Healthy living and cancer: evidence from UK Biobank.
Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.
Hereditary prostate cancer: clinical aspects.
Heterogeneity in prostate cancer: prostate specific antigen (PSA) and DNA cytophotometry.
High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study.
High Incidence of Predominant Gleason Pattern 4 Localized Prostate Cancer is Associated With Low Serum Testosterone.
High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer.
High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer.
High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry.
High-Throughput Electrochemical Microfluidic Immunoarray for Multiplexed Detection of Cancer Biomarker Proteins.
High-throughput quantitative analysis of total N-glycans by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases.
Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression.
Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
Hormone therapy of prostatic bone metastases.
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors.
Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer.
Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Human prostate cancer model: roles of growth factors and extracellular matrices.
Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein.
Human prostatic acid phosphatase and prostate specific antigen: protein structure, gene organization, and expression in neoplastic and benign tissues.
Human tissue kallikreins: a family of new cancer biomarkers.
Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence.
Hypertrophic osteoarthropathy as the cause of a super scan of the bone in a patient with prostate cancer: a case report.
Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.
Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases.
Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.
Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
Identification of six novel alternative transcripts of the human kallikrein-related peptidase 15 (KLK15), using 3'RACE and high-throughput sequencing.
Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes.
Image-guided focal therapy for prostate cancer.
Image-guided radiotherapy reduces the risk of under-dosing high-risk prostate cancer extra-capsular disease and improves biochemical control.
Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
Immune response to sipuleucel-T in prostate cancer.
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer.
Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer.
Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers.
Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
Impact of capillary conditioning and background electrolyte composition on capillary electrophoresis analysis of prostate specific antigen isoforms.
Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening.
Impact of increased number of biopsies on the nature of prostate cancer identified.
Impact of low prostate specific antigen on prostate cancer--a rare case report.
Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database.
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Impact of the evolving United States Preventative Services Task Force policy statements on incidence and distribution of prostate cancer over 15 years in a statewide cancer registry.
Impedimetric aptamer-based glycan PSA score for discrimination of prostate cancer from other prostate diseases.
Impedimetric PSA aptasensor based on the use of a glassy carbon electrode modified with titanium oxide nanoparticles and silk fibroin nanofibers.
Implications of a new element in the early diagnostic pathway for prostate cancer for rural Australians.
Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).
Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels.
Improving Detection of Clinically Significant Prostate Cancer: Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Guided Prostate Biopsy.
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.
In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
In-bore MRI targeted biopsy.
Inactive free : total prostate specific antigen ratios in ejaculate from men with suspected and known prostate cancer, compared with young control men.
Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography.
Incidental Hydroxyapatite Ocular Implant Uptake on Bone Scan Done for Prostate Cancer Staging: Case Report and Brief Review
Incidental possible diagnosis by 18F-fluorocholine PET/CT of Meckel's diverticulum and potential pitfalls.
Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Increased peripheral CD4+CD25high Treg in prostate cancer patients is correlated with PSA.
Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study.
Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells.
Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Increasing incidence of prostate cancer in Taiwan: A study of related factors using a nationwide health and welfare database.
Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer.
Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine.
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml.
Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection.
Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17?-estradiol in prostate cancer.
Inhibition of prostate specific antigen expression by genistein in prostate cancer cells.
Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid.
Inhibitory effect of matrine on the expression of PSA and AR in prostate cancer cell line LNCaP.
Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
Initiation of salvage therapy for prostate cancer.
INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer.
Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Integration of quantitative diffusion kurtosis imaging and prostate specific antigen in differential diagnostic of prostate cancer.
Intensive lifestyle changes may affect the progression of prostate cancer.
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial.
Interleukin-1? promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Interleukin-6 polymorphism is associated with more aggressive prostate cancer.
Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer.
Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer.
Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6year screening interval.
Intracranial metastasis of prostate cancer: report of two cases.
Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Intron retention: a common splicing event within the human kallikrein gene family.
Inverse Relationship between PSA and IL-8 in Prostate Cancer: An Insight into a NF-?B-Mediated Mechanism.
Involvment of IL-1 beta Mediated NF-Kappa B Signalling Payhways to Downregulate Prostate Specific Antigen And Cell Proliferation in LNCaP Prostate Cancer Cells.
Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?
Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies?
Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution).
Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature.
Is magnetic resonance imaging helpful in detecting significant prostate cancer in patients with haematospermia, normal prostate specific antigen level and digital rectal examination. A single institution, observational, and retrospective study in a United Kingdom hospital.
Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population?
Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy?
Is race a positive predictor of cancer on repeat prostate biopsy?
Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia?
Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse?
Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population?
Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era?
Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer.
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Joint latent class models for longitudinal and time-to-event data: A review.
Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
Kallikreins are involved in an miRNA network that contributes to prostate cancer progression.
Kallikreins as biomarkers for prostate cancer.
Kinetic analysis of prostatic volume and prostate specific antigen (PSA) in patients with advanced prostatic cancer treated by castration.
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Knockdown of scavenger receptor class B Type I reduces prostate specific antigen secretion and viability of prostate cancer cells.
Knowledge of prostate cancer screening among native African urban population in Nigeria.
Knowledge, attitudes and practices of Ugandan men regarding prostate cancer.
Labeless immunosensor assay for prostate specific antigen with picogram per milliliter limits of detection based upon an ac impedance protocol.
Laparoscopic pelvic lymph node dissection.
Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen.
Large-scale propagation of recombinant adherent cells that secrete a stable form of human glandular kallikrein, hK2.
Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies.
Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Lead-time in the European Randomised Study of Screening for Prostate Cancer.
Learning to improve safety: false-positive pathology report results in wrongful surgery.
Leptin influences cellular differentiation and progression in prostate cancer.
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Levels of prostate specific antigen that predict skeletal spread in prostate cancer.
Liarozole.
Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
Lifestyle and prostate cancer among older African-American and Caucasian men in South Carolina.
Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada.
Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer.
Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database.
Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.
Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada.
LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen.
Local-regional prostate cancer.
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study.
Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment.
Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells.
Low expression of Galpha protein subunits in human prostate cancer.
LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE?
Lower urinary tract symptoms and risk of prostate cancer in Japanese men.
Lower use of prostate specific antigen testing by cigarette smokers-Another possible explanation for the unfavorable prostate cancer (PCA) specific prognosis in smokers?
Lymph node positive prostate cancer: long-term survival data after radical prostatectomy.
Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.
Malignant Ascites Associated with Carcinoma of the Prostate.
Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure.
Management of hormone resistant prostate cancer.
Management of Low Risk and Low PSA Prostate Cancer: Long Term Results from the Prostate Cancer Intervention Versus Observation Trial.
Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy?
Markers for detection of prostate cancer.
Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.
Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen.
Mass screening of prostate cancer in Changchun City of China.
Mass Spectrometry-Based Glycoproteomics and Prostate Cancer.
Mass-tag enhanced immuno-laser desorption/ionization mass spectrometry for sensitive detection of intact protein antigens.
Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy.
Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Measurement of prostate specific antigen as screening test for prostate cancer. False positive results cast doubt on conclusion.
Measurement of prostate specific antigen as screening test for prostate cancer. Measurement presents technical difficulties.
Measurement of prostate specific antigen as screening test for prostate cancer. Paper gives misleadingly optimistic view.
Measurement of prostate specific antigen as screening test for prostate cancer. Trials of treatment are needed before trials of screening.
Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique.
Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.
Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds.
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen.
Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.
Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes.
Metabolic Atrophy and 3T 1H - MR Spectroscopy Correlation After Radiation Therapy for Prostate Cancer.
Metastasis on Bone Scan With Low Prostate Specific Antigen (? 20 ng/ml) and Gleason's Score (<8) in Newly Diagnosed Pakistani Males with Prostate Cancer: Should We Follow Western Guidelines?
Metastatic prostate cancer to lung with normal prostate specific antigen levels.
Metastatic prostate cancer: complications and treatment.
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.
Methylation and MicroRNA Profiling to Understand Racial Disparities of Prostate Cancer.
Microfluidic integration for automated targeted proteomic assays.
Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
Mining laboratory data to describe prostate specific antigen testing and prostate cancer in Johannesburg, South Africa.
miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.
Mitochondria, prostate cancer, and biopsy sampling error.
Mn-doped ZnSe d-dots-based ?-methylacyl-CoA racemase probe for human prostate cancer cell imaging.
Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study.
Modeling Disease Progression with Longitudinal Markers.
Modeling the overdetection of screen-identified cancers in population-based cancer screening with the Coxian phase-type Markov process.
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer.
Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.
Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Molecular markers for prostatic cancer.
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.
Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization.
Molecular sampling of prostate cancer: a dilemma for predicting disease progression.
Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
Monitoring percent free PSA in serial specimens: improvement of test specificity, early detection, and identification of occult tumors.
More information on prostate specific antigen and prostate cancer.
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Mortality reductions produced by sustained prostate cancer screening have been underestimated.
MRI of the skeleton in prostate cancer staging.
MRI/TRUS FUSION guided biopsy as first approach in ambulatory setting: Feasibility and performance of a new fusion device.
Multianalyte quantitative competitive PCR on optically encoded microspheres for an eight-gene panel related to prostate cancer.
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.
Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer.
Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
Multimarker circulating DNA assay for assessing blood of prostate cancer patients.
Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients.
Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves But Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer.
Multiparametric MRI in the PSA screening era.
Multiple imputation for threshold-crossing data with interval censoring.
Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ((18)F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.
Multivariate statistical analysis for pathologist. Part I, The logistic model.
Nanomaterial based aptasensing of prostate specific antigen (PSA): Recent progress and challenges in efficient diagnosis of prostate cancer using biomedicine.
Nanomaterial-based biosensors for detection of prostate specific antigen.
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.
National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Natural history of changes in prostate specific antigen in early stage prostate cancer.
Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators.
Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy.
Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
Neoadjuvant Hormone Therapy Before Radical Prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center Trials.
Nephrogenic adenoma of the prostatic urethra: a mimicker of prostate adenocarcinoma.
Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer.
Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer.
New biomarkers for diagnosis and prognosis of localized prostate cancer.
New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
New circulating biomarkers for prostate cancer.
New serum tests for the diagnosis of prostate cancer.
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.
No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination.
Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL.
Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study.
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer.
Not all patients pursue prostate biopsy after abnormal prostate specific antigen results.
Novel Biomarkers for Prostate Cancer Detection and Prognosis.
Novel diagnostic biomarkers of prostate cancer: an update.
Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers.
Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer.
Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks.
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells.
Obesity and prostate cancer.
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
Octreotide in advanced prostatic cancer relapsing under hormonal treatment.
Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
One-year experience with 68Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer.
Operational Characteristics of (11)C-Choline Positron Emission Tomography/Computerized Tomography for Prostate Cancer with Biochemical Recurrence After Initial Treatment.
Opportunistic prostate cancer screening: A population-based analysis.
Optimal use of prostate specific antigen for prostate cancer screening.
Optimising the management of early prostate cancer.
Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
Oral chemotherapy in the treatment of hormone-refractory prostate cancer.
Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.
Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
Outcome based staging for clinically localized adenocarcinoma of the prostate.
Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy.
Outcome of radical prostatectomy as primary treatment for high-risk prostate cancer patients.
Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer.
Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.
Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results.
Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
p,p'-Dichlorodiphenyltrichloroethane (p,p'-DDT) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) repress prostate specific antigen levels in human prostate cancer cell lines.
Paget's disease of bone in ethnic Thai presented with urologic symptoms and misleading as metastatic prostate cancer: report of a case with a review of the literature.
Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.
Pan-cadherin as a high level phenotypic biomarker for prostate cancer.
Parameter identification of a model for prostate cancer treated by intermittent therapy.
Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?
Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer.
Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors.
Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.
Patterns of Local Failure following Radiation Therapy for Prostate Cancer.
PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer.
PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells.
PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
PCA3: from basic molecular science to the clinical lab.
Pelvic lymphadenectomy for localized prostate cancer.
Penile metastasis from carcinoma of the prostate in a patient with high serum prostate specific antigen levels.
Peptide-nanoparticle hybrid SERS probes for optical detection of protease activity.
Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Percent free PSA as an additional measure in a prostate cancer screen.
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
Perceptions of Prostate Cancer Fatalism and Screening Behavior Between United States-Born and Caribbean-Born Black Males.
Performance of Prostate Health Index in Biopsy Naïve Black Men.
Performance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical Samples.
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.
Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality.
Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Personalized approach to prostate cancer prognosis.
Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies.
Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
PET-CT for treatment planning in prostate cancer.
PET/CT variants and pitfalls in prostate cancer: What you might see on PET and should never forget.
Phage display aided improvement of a unique prostate-specific antigen (PSA) antibody unreactive with Lys(145)-Lys(146) internally cleaved forms.
Phage display screening identifies a prostate specific antigen (PSA)-/lo prostate cancer cell specific peptide to retard castration resistance of prostate cancer.
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Phase I study of phenylacetate administered twice daily to patients with cancer.
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
PHI in the Early Detection of Prostate Cancer.
Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance.
Piflufolastat F 18: Diagnostic First Approval.
Pitfalls in interpreting prostate specific antigen velocity.
Pitfalls of hormonal injection therapy in prostate cancer.
Pituitary metastasis of prostate cancer presenting as a unilateral third nerve palsy.
Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.
Plasma sialic acid in patients with prostate cancer.
Polyamine deprivation provokes an antalgic effect.
Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.
Pomegranate and its components as alternative treatment for prostate cancer.
Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland.
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes.
Population standards of prostate specific antigen values in men over 40: community based study in Turkey.
Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.
Positive correlation of serum parathormone and prostate specific antigen levels in prostate cancer.
Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis.
Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6.
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality.
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Potential selection bias in a community-based study of PSA levels in African-American men.
Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.
Powerful Chemiluminescence Probe for Rapid Detection of Prostate Specific Antigen Proteolytic Activity: Forensic Identification of Human Semen.
Practice patterns of Korean urologists for screening and managing prostate cancer according to PSA level.
Practice trends in the diagnosis and management of prostate cancer in the United States.
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.
Pre-operative Percent Free PSA Predicts Clinical Outcomes in Patients Treated with Radical Prostatectomy with Total PSA Levels below 10ng/ml.
Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy.
Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume.
Predicting Pelvic Lymph Node Involvement in Current-Era Prostate Cancer.
Predicting Prostate Biopsy Outcomes: A Preliminary Investigation on Screening with Ultrahigh B-Value Diffusion-Weighted Imaging as an Innovative Diagnostic Biomarker.
Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay.
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers.
Predicting prostate cancer risk through incorporation of prostate cancer gene 3.
Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer.
Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era.
Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm.
Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.
Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate.
Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.
Predictive factors of prostate cancer diagnosis with PSA 4.0-10.0 ng/ml in a multi-ethnic Asian population, Malaysia.
Predictive Value of Neutrophil to Lymphocyte Ratio in the Diagnosis of Significant Prostate Cancer at Initial Biopsy: A Comparison with Free Percent Prostate Specific Antigen, Prostate Specific Antigen Density and Primary Circulating Prostate Cells.
Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach.
Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy.
Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
Predictors of histological disease progression in untreated, localized prostate cancer.
Predictors of prostate cancer after initial negative systematic 12 core biopsy.
Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen.
Preliminary Case Series of Artemisinin for Prostate Cancer in a Naturopathic Practice.
Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer.
Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage.
Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Preoperative prostate specific antigen and prostate volume are significant predictors of seminal vesicle invasion in patients with prostate cancer.
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy.
Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Preperitoneal mesh-plug herniorraphy during radical retropubic prostatectomy.
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients.
Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer.
Prevalence and associations of general practitioners' ordering of "non-symptomatic" prostate-specific antigen tests: A cross-sectional analysis.
Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination.
Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.
Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml.
Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate.
Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Prevalence of undiagnosed prostate cancer in men with erectile dysfunction.
Prevention of benign prostatic hyperplasia disease.
Primary cryoablation nadir prostate specific antigen and biochemical failure.
Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center.
Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Probability of prostate cancer at various levels of per cent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml.
Problems in the determination of prostate specific antigen.
Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa.
Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels.
Production and Characterization of Monoclonal Antibodies against Human Prostate Specific Antigen.
Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques.
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Prognostic importance of PSA response in patients who received Lutetium-177 PSMA treatment for castration resistant prostate cancer.
Prognostic significance of a novel indicator (PSApostd3/PSApre) for PSA recurrence in patients after radical prostatectomy.
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies.
Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.
Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment.
Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
Progression of prostate cancer despite undetectable serum prostate specific antigen.
Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer.
Promoting informed decision making about prostate cancer screening.
Proper cut-off value of free to total PSA ratio for detection of prostate cancer in Korean men.
Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden.
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Prospective evaluation of prostate cancer risk in candidates for inguinal hernia repair.
Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels.
Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.
Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer.
Prospects in radionuclide imaging of prostate cancer.
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale?
Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ml after Treatment with 5?-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer.
Prostate biopsy in the diagnosis of prostate cancer: current trends and techniques.
Prostate biopsy.
Prostate Cancer and Its Mimics at Multiparametric Prostate MRI.
Prostate cancer and microfluids.
Prostate cancer and prostate specific antigen. A Jamaican perspective.
Prostate cancer and sarcoma: Challenges of synchronous malignancies.
Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy.
Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population.
Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Prostate cancer detection at low prostate specific antigen.
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen.
Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990.
Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml.
Prostate cancer detection in candidates for open prostatectomy.
Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
Prostate cancer detection in veterans with a history of Agent Orange exposure.
Prostate cancer detection is also relevant in low prostate specific antigen ranges.
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice.
Prostate cancer diagnosis: should patients with prostate specific antigen >10ng/mL have stratified prostate biopsy protocols?
Prostate Cancer Diagnostic Algorithm as a "Road Map" from the First Stratification of the Patient to the Final Treatment Decision.
Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy.
Prostate cancer in general practice. Results of a five year prospective clinical study in one practice.
Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.
Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.
Prostate cancer in renal transplant recipients.
Prostate cancer in Saskatchewan Canada, before and during the PSA era.
Prostate cancer in senior adults: over- or undertreated?
Prostate cancer in Victoria in 1993: patterns of reported management.
Prostate cancer incidence and mortality in Navarre (Spain).
Prostate cancer incidence and mortality in Portugal: trends, projections and regional differences.
Prostate cancer incidence and survival in relation to education (United States).
Prostate cancer incidence, mortality, total and free prostate specific antigen.
Prostate cancer management: (1) an update on localised disease.
Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men.
Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics.
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Prostate cancer prevention and finasteride.
Prostate cancer radiotherapy dose response: an update of the fox chase experience.
Prostate Cancer Risk Alleles Are Associated with Prostate Cancer Volume and Prostate Size.
Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
Prostate cancer risk assessment program: a 10-year update of cancer detection.
Prostate cancer risk is three-fold higher among men, aged 50-64, of African descent compared with men of Asian-Indian descent in Trinidad and Tobago.
Prostate cancer screening before and after abdominoperineal resection: recommendations, biopsy, and therapeutic techniques.
Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions.
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
Prostate cancer screening perceptions, knowledge and behaviors among African American men: focus group findings.
Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012.
Prostate cancer screening with prostate specific antigen in spinal cord injured men.
Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Prostate cancer screening--a physician survey in Missouri.
Prostate cancer screening.
Prostate Cancer Screening.
Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.
Prostate cancer update: 2005.
Prostate cancer update: 2006.
Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?
Prostate cancer.
Prostate cancer: A challenge for screening.
Prostate Cancer: An Evolving Paradigm.
Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens.
Prostate cancer: diagnostic and therapeutic strategies with emphasis on the role of PSA.
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
Prostate saturation biopsy in the reevaluation of microfocal prostate cancer.
Prostate screening in patients with 46,XY disorders of sex development--is it necessary?
Prostate screening--the Singapore experience.
Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels.
Prostate sparing cystectomy for bladder cancer: A two-center study.
Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) immunoreactivity in benign seminal vesicle\ejaculatory duct epithelium: a potential pitfall in the diagnosis of prostate cancer in needle biopsy specimens.
Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis.
Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients.
Prostate specific antigen (PSA) testing as screening for prostate cancer: the current controversy.
Prostate specific antigen (PSA) value adjusted for transition zone volume and free PSA (gamma-seminoprotein)/PSA ratio in the diagnosis of prostate cancer in patients with intermediate PSA levels.
Prostate specific antigen - useful screening tool or potential liability?
Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer.
Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.
Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University.
Prostate specific antigen and benign prostatic hyperplasia.
Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.
Prostate specific antigen and Gleason score in men with prostate cancer at a private diagnostic radiology centre in Western Jamaica.
Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer.
Prostate specific antigen and other markers for prostate cancer.
Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report.
Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management.
Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.
Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate.
Prostate specific antigen and screening for early prostate cancer.
Prostate Specific Antigen as a Clinical Biomarker for Prostate Cancer: What's the Take Home Message?
Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.
Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Prostate specific antigen assay standardization bias could affect clinical decision making.
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty.
Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer.
Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.
Prostate specific antigen change after administration of nimotuzumab in prostate cancer.
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
Prostate Specific Antigen Decrease and Prostate Cancer Diagnosis: Recognizing the Fundamental Previous Progresses and Moving Forward.
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.
Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction.
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.
Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies.
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Prostate specific antigen detected prostate cancer.
Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.
Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
Prostate specific antigen following radiotherapy for local prostate cancer.
Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Prostate specific antigen for detecting early prostate cancer.
Prostate specific antigen for early detection of prostate cancer: longitudinal study.
Prostate specific antigen for screening for prostate cancer: an appraisal of Thai reports.
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism.
Prostate specific antigen in as a dynamic model in advanced prostate cancer.
Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment.
Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer.
Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade.
Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer.
Prostate specific antigen in the diagnosis and staging of prostate cancer.
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.
Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer.
Prostate specific antigen isoforms and human glandular kallikrein 2--which offers the best screening performance in a predominantly black population?
Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
Prostate specific antigen kinetics in the management of prostate cancer.
Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer.
Prostate specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low risk prostate cancer.
Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease.
Prostate specific antigen levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical prostatectomy?
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.
Prostate specific antigen mass ratio potential as a prostate cancer screening tool.
Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.
Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design.
Prostate specific antigen only progression of prostate cancer.
Prostate specific antigen patterns in US and European populations: comparison of six diverse cohorts.
Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer.
Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature.
Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer.
Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians.
Prostate specific antigen testing after radical prostatectomy: can we stop at 20 years?
Prostate specific antigen testing among the elderly--when to stop?
Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
Prostate specific antigen testing for prostate cancer.
Prostate specific antigen testing for the diagnosis of prostate cancer.
Prostate specific antigen testing in men older than 75 years in the United States.
Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study.
Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
Prostate specific antigen variation in patients without clinically evident prostate cancer.
Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset.
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia
Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera.
Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
Prostate specific antigen. Experimental and clinical observations.
Prostate specific antigen: a decade of discovery--what we have learned and where we are going.
Prostate specific antigen: a useful screening test?
Prostate specific antigen: biology, biochemistry and available commercial assays.
Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy.
Prostate specific antigen: the past, present and future.
Prostate tissue and serum markers.
Prostate tumour markers and differentiation grade in prostatic cancer.
Prostate tumour markers as an aid in the staging of prostatic cancer.
Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.
Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men.
Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome.
Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Prostate-specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-control Study.
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Prostate-specific antigen testing and prostate cancer screening.
Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.
Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.
Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis.
Prostatic cancer: hospital-based prostate specific antigen screening.
Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Prostatic zinc and prostate specific antigen: an experimental evaluation of their combined diagnostic value.
Protein Counting in Single Cancer Cells.
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer.
Proteomics of human prostate cancer biospecimens: the global, systems-wide perspective for Protein markers with potential clinical utility.
PSA density (PSAD). Role in patient evaluation and management.
PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia.
PSA relapse prostate cancer: the importance of tailored therapy.
PSA screening: a public health dilemma.
PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.
PSA testing: are patients aware of what lies ahead?
PSA-based machine learning model improves prostate cancer risk stratification in a screening population.
PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach.
PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Psychological Distress and Prostate Specific Antigen Levels in Men with and without Prostate Cancer.
Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer.
Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.
Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry.
Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment.
Quantitative PSA RT-PCR for preoperative staging of prostate cancer.
Quebec prostate cancer mortality dropped in 1996.
Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer.
Race, Decisional Regret and Prostate Cancer Beliefs: Identifying Targets to Reduce Racial Disparities in Prostate Cancer.
Racial differences in operating characteristics of prostate cancer screening tests.
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.
Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study.
Racial variation in prostate specific antigen in a large cohort of men without prostate cancer.
Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes.
Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
Radical perineal prostatectomy: oncological outcome during a 20-year period.
Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.
Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.
Radical prostatectomy in men less than 50 years old.
Radical prostatectomy nomograms in black American men: accuracy and applicability.
Radical prostatectomy, radiotherapy or deferred treatment for localized prostate cancer?
Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence.
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.
Radiotherapy for a rising PSA following radical prostatectomy.
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance.
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Rapid aptasensor capable of simply diagnosing prostate cancer.
Rapid Diagnosis of Prostate Cancer Disease Progression Using Paper Spray Ionization Mass Spectrometry.
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.
Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.
Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Ratio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.
Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001.
Re: complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation.
Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer.
Re: Endogenous and Exogenous Testosterone and the Risk of Prostate Cancer and Increased Prostate Specific Antigen (PSA): A Meta-Analysis.
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial.
Re: no increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination.
Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
Re: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Re: prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Re: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.
Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.
Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Polascik J Urol 2018; 200: 758-766.
Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Re: radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
Re: Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening: E. A. Vertosick, B. Y. Poon and A. J. Vickers J Urol 2014;192:724-729.
Re: reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.
Re: Serum prostate specific antigen as prescreening test for prostate cancer.
Re: Strategy for Detection of Prostate Cancer Based on Relation Between Prostate Specific Antigen at Age 40-55 and Long Term Risk of Metastasis: Case-control Study.
Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265.
Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
Re: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
Re: Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
Reactions to Recommendations and Evidence About Prostate Cancer Screening Among White and Black Male Veterans.
Real-time elastography for detecting prostate cancer: preliminary experience.
Real-Time Individual Predictions of Prostate Cancer Recurrence Using Joint Models.
Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer.
Real-time prostate-specific antigen detection with prostate-specific antigen imprinted capacitive biosensors.
Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate.
Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
Recent progress in hormonal therapy for advanced prostate cancer.
Recent trends in prostate cancer mortality show a continuous decrease in several countries.
Receptor gene messenger RNA expression in metastatic lesions of prostate cancer.
Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness.
Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Recommendations by Canadian urologists and radiation oncologists for the treatment of clinically localized prostate cancer.
Reconnoitring the status of prostate specific antigen and its role in women.
Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
Recurrent prostate cancer despite undetectable prostate specific antigen.
Recurrent PSA after prostatectomy for prostate cancer: implications of PSA doubling time.
Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up.
Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study.
Relationship between prostate specific antigen, prostate volume and age in the benign prostate.
Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men.
Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer.
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.
Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate.
Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project.
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer.
Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese.
Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer.
Results of compliance with prostate cancer screening guidelines.
Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Reversed association between levels of prostate specific antigen and levels of blood cadmium and urinary cadmium.
Review of clinical manifestations of biochemically-advanced prostate cancer cases.
Rising prostate specific antigen after radical prostatectomy: a case based review.
Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Risk Prediction for Prostate Cancer Recurrence Through Regularized Estimation with Simultaneous Adjustment for Nonlinear Clinical Effects.
Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells.
Robot-Assisted Laparoscopic Radical Prostatectomy 6 Months After Rectal Spacer Hydrogel Injection.
Robotic radical prostatectomy in the community setting--the learning curve and beyond: initial 200 cases.
Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness.
Role of complexed PSA in the early detection of prostate cancer.
Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer.
Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases.
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
Role of prostate specific antigen and prostate specific antigen density as biomarkers for medical and surgical treatment response in men with lower urinary tract symptoms: a systematic review and meta-analysis.
Role of prostate volume in the early detection of prostate cancer in a cohort with slowly increasing prostate specific antigen.
Routine screening by prostate specific antigen for prostate cancer seems unreasonable.
Rye Whole Grain and Bran Intake Compared with Refined Wheat Decreases Urinary C-Peptide, Plasma Insulin, and Prostate Specific Antigen in Men with Prostate Cancer.
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.
Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: is it possible to identify patients likely to have good treatment outcomes?
Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography.
Salvage options for biochemical recurrence after primary therapy for prostate cancer.
Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.
Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges.
Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling.
Sample preparation of serum to allow capillary electrophoresis analysis of prostate specific antigen isoforms.
Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer.
Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer.
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against.
Screening for cancer. Is it useful?
Screening for carcinoma of the prostate: a GP based study.
Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins.
Screening for prostate cancer using multivariate mixed-effects models.
Screening for prostate cancer with PSA testing: current status and future directions.
Screening for prostate cancer--how to manage in 2006?
Screening for prostate cancer. Comparison of transrectal ultrasound, prostate specific antigen and rectal examination.
Screening for prostate cancer. Does it make a difference?
Screening for prostate cancer: a survey of New Zealand general practitioners.
Screening for prostate cancer: an update.
Screening for Prostate Cancer: Current Status of ERSPC and Screening-Related Issues.
Screening for prostate cancer: moving forward in the molecular era.
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.
Screening for prostate cancer: the current evidence and guidelines controversy.
Screening for prostate cancer: what do general practitioners think?
Screening strategies: a clinical perspective.
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.
Seminal exosomes - An important biological marker for various disorders and syndrome in human reproduction.
Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results.
Seminal vesicle biopsy in prostate cancer staging.
Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Sensors for diagnosis of prostate cancer: Looking beyond the prostate specific antigen.
Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.
Ser-486/491 phosphorylation and inhibition of AMPK? activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies.
Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.
Serum BSP, PSADT, and Spondin-2 levels in prostate cancer and the diagnostic significance of their ROC curves in bone metastasis.
Serum ceruloplasmin as a marker in prostate cancer.
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.
Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate.
Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer.
Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
Serum insulin-like growth factor-1 is not a useful marker of prostate cancer.
Serum lactate dehydrogenase in combination with free-to-total serum prostate specific antigen ratio for diagnosis of prostate cancer.
Serum levels of prostate specific antigen in men on hemodialysis.
Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Serum levels of total and free prostate specific antigen in men on hemodialysis.
Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
Serum prostate specific antigen and prostate specific antigen density in patients receiving radical prostatectomy.
Serum prostate specific antigen as pre-screening test for prostate cancer.
Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.
Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.
Serum Testosterone, 17?-Estradiol and PSA Levels in Subjects with Prostate Disorders.
Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml.
Set-up and preliminary results from the Patient-overview Prostate Cancer. Longitudinal registration of treatment of advanced prostate cancer in the National Prostate Cancer Register of Sweden.
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial.
Should baseline PSA testing be performed in men aged 40 to detect those aged 50 or less who are at risk of aggressive prostate cancer?
Should Prostate Specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.
Signal-on electrochemical aptasensors with different target-induced conformations for prostate specific antigen detection.
Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
Significance of measurement of prostate specific antigen (PSA) in familial prostate cancer lines.
Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients.
Significance of serum free prostate specific antigen in the screening of prostate cancer.
Significance of serum total prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer.
Significance of the prostate central gland and total gland volume ratio in the diagnosis of prostate cancer patients in the prostate specific antigen grey zone.
Significant association of metabolic indices, lipid profile, and androgen levels with prostate cancer.
Silver nanoparticles deposited on graphene oxide for ultrasensitive surface-enhanced Raman scattering immunoassay of cancer biomarker.
Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Simultaneous detection of circulating prostate specific antigen (PSA)-expressing and prostate specific membrane antigen (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Simultaneous Detection of Dual Prostate Specific Antigens Using Surface-Enhanced Raman Scattering-Based Immunoassay for Accurate Diagnosis of Prostate Cancer.
Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level.
Single-dose antibiotic prophylaxis in core prostate biopsy: impact of timing and identification of risk factors.
Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China.
Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups.
Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Socioeconomic variation and prostate specific antigen testing in the community: a United kingdom based population study.
Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening.
Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.
Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy.
Soluble N-cadherin in human biological fluids.
Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men.
Spectrum of prostate cancer in the Singapore General Hospital (1980 to 1985).
Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells.
Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer.
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures.
Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease.
Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions.
Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Standardization of PSA determinations.
Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
Stat3 enhances transactivation of steroid hormone receptors.
Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer.
Statistical models for longitudinal biomarkers of disease onset.
Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation.
Storm over screening for prostate specific antigen. Give men facts on prostate cancer.
Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
Streamlining immunoassays with immiscible filtrations assisted by surface tension.
Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
SU-E-T-227: Re-Evaluation of Dose Distribution and Margins for IMRT Prostate Plans.
Sub-zeptomole Detection of Biomarker Proteins Using a Microfluidic Immunoarray with Nanostructured Sensors.
Subcutaneous Fat Distribution Is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology.
Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4.
Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for.
Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.
Supraclavicular lymph node as the first presentation and late skin metastasis: an unusual clinical course for prostate cancer.
Surgical and oncological outcomes in patients with a preoperative PSA value <4 ng/ml undergoing robot-assisted radical prostatectomy.
Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy.
Surgical approaches to local failure after definitive therapy.
Surgical management of high risk prostate cancer: the Mayo Clinic experience.
Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden.
Survey of the rate of PSA testing in general practice.
Survival Among Men With Clinically Localized Prostate Cancer Treated With Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era.
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.
Survival of prostate cancer patients in central and northern Denmark, 1998-2009.
Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy.
Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15.
Systematic sextant biopsies in 651 patients referred for prostate evaluation.
Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.
Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.
Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives.
Targeting thapsigargin towards tumors.
Targeting Tumor Markers with Antisense Peptides: An Example of Human Prostate Specific Antigen.
Technological aspects of delivering cryotherapy for prostate cancer.
Tendencies of mortality by prostate cancer in the states of the Central-West Region of Brazil, 1980-2011.
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Testing the variability of PSA expression by different human prostate cancer cell lines by means of a new potentiometric device employing molecularly antibody assembled on graphene surface.
Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells.
Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Testosterone Replacement in Men with Treated and Untreated Prostate Cancer.
Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy.
Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells.
Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development.
The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.
The 11?-hydroxysteroid dehydrogenase isoforms: pivotal catalytic activities yield potent C11-oxy C19 steroids with 11?HSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis.
The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.
The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required?
The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE).
The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients.
The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men.
The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model.
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
The application of the RT-PCR method for the staging of the prostate cancer progression.
The arachidonic Acid pathway and its role in prostate cancer development and progression.
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer.
The association between total prostate specific antigen concentration and prostate specific antigen velocity.
The Association of Veterans' PSA Screening Rates with Changes in USPSTF Recommendations.
The Benefit of a Surgical Resection of a Solitary Pulmonary Metastasis of Prostate Cancer after Radical Prostatectomy.
The biologic lower detection limit of six ultrasensitive PSA assays.
The case for adjuvant therapy for prostate cancer.
The central role of prostate specific antigen in diagnosis and progression of prostate cancer.
The Chance of Small Interfering RNAs as Eligible Candidates for a Personalized Treatment of Prostate Cancer.
The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study.
The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer.
The complexity of PSA interpretation in clinical practice.
The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
The correlation between the gleason score of the biopsy and that of the prostatectomy patch.
The Cuban Institute of Oncology and Radiobiology experience on the beliefs and opinions about digital rectal exam in urological patients.
The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
The Design and Evaluation of a Computerized and Physical Simulator for Training Clinical Prostate Exams.
The detection of prostate specific antigen, MHS-5, and other markers in invasive prostate cancer and seminal vesicle.
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate.
The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p.
The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age.
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
The effect of finasteride on prostate specific antigen: review of available data.
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.
The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
The effect of pelvic radiation therapy on serum levels of prostate specific antigen.
The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.
The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report.
The Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies.
The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience.
The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.
The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA.
The eternal enigma in prostatic biopsy access route.
The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population.
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells.
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
The impact of educational sessions provided on prostate cancer, and its screening tests on the knowledge level, and participation behavior of the individuals in questionnaire surveys.
The impact of inadequate knowledge on patient and spouse experience of prostate cancer.
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer.
The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance.
The impact of prostate cancer knowledge on cancer screening.
The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml.
The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer.
The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.
The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy.
The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.
The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels.
The lady with raised prostate specific antigen: do we need to worry?
The Magnetic Resonance Imaging in Active Surveillance "MRIAS" Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer.
The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
The natural history of androgen independent prostate cancer.
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
The nature of prostate cancer detected through prostate specific antigen based screening.
The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies.
The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
The number of tPSA tests continues to rise and variation in testing practices persists: a survey of laboratory services in Ireland 2008-2010.
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ?65 years.
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
The prevalence of prostate cancer screening in Thai elderly.
The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer.
The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate.
The Prostate Cancer gene 3 assay: indications for use in clinical practice.
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
The prostate specific antigen. Its use as a tumor marker for prostate cancer.
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context.
The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
The Ratio of Serum Testosterone-to-Prostate Specific Antigen Predicts Prostate Cancer in Hypogonadal Men.
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
The relationship between Agent Orange and prostate specific antigen: a comparison of a hotspot and a non-sprayed area in Vietnam.
The Relationship Between Prostate Specific Antigen Change and Biopsy Progression in Patients With Prostate Cancer on Active Surveillance.
The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection.
The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
The role of digital rectal examination, transrectal ultrasound, and prostate specific antigen for the detection of confined and clinically relevant prostate cancer.
The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml.
The role of external radiotherapy in patients treated with permanent prostate brachytherapy.
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
The role of lipid-associated sialic acid (LSA) and prostate specific antigen (PSA) in the follow-up of prostatic cancer.
The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.
The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
The role of pelvic lymphadenectomy for prostate cancer--therapeutic?
The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening.
The role of power Doppler ultrasonography in the diagnosis of prostate cancer: a preliminary study.
The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.
The role of prostate specific antigen in screening and management of clinically localized prostate cancer.
The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
The role of prostate specific antigen measurement in the detection and management of prostate cancer.
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
The role of PSA in detection and management of prostate cancer.
The Role of PSA Monitoring after Holmium Laser Enucleation of the Prostate (HoLEP).
The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer.
The role of the androgen receptor as a driver and mitigator of cellular stress.
The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule.
The second largest subunit of RNA polymerase II interacts with and enhances transactivation of androgen receptor.
The significance of monoamine oxidase-A expression in high grade prostate cancer.
The Significance of Prostate Specific Antigen Persistence in Prostate Cancer Risk Groups on Long-Term Oncological Outcomes.
The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.
The trends in prostate specific antigen usage amongst United Kingdom urologists--a questionnaire based study.
The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence.
The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.
The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL.
The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice.
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
The use of prostate specific antigen density to predict clinically significant prostate cancer.
The use of prostate specific antigen for prostate cancer screening: a managed care perspective.
The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database.
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
The Utility and Limitations of Contrast-Enhanced Ultrasound for the Diagnosis and Treatment of Prostate Cancer.
The utility of free to total PSA ratio for detecting prostate cancer in Japanese men with total PSA between 2.1 and 10 ng/ml.
The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen.
The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy.
The value of endorectal MRI in the early diagnosis of prostate cancer.
The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
The value of gamma-seminoprotein in combination with prostate specific antigen in detecting prostate cancer.
The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0-10.0 ng/mL) in Nigeria.
The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913.
The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view.
The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.
The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume.
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.
Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer.
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Tin Oxide Nanosheet Assembly for Hydrophobic/Hydrophilic Coating and Cancer Sensing.
Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers.
Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway.
Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer.
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments.
Toward the detection of prostate cancer in urine: a critical analysis.
Towards the differential diagnosis of prostate cancer by the pre-treatment of human urine using ionic liquids.
Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer.
Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role.
Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.
Transperineal magnetic resonance image guided prostate biopsy.
Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies.
Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study.
Transrectal power Doppler imaging in the detection of prostate cancer.
Transrectal real-time elastography-guided transperineal prostate biopsy as an improved tool for prostate cancer diagnosis.
Transrectal sonography in prostate cancer detection--our 25 years experience of implementation.
Transrectal ultrasound in the diagnosis and staging of local disease after I125 seed implantation for prostate cancer.
Transrectal ultrasound-guided prostate biopsy in Taiwan: A nationwide database study.
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Treatment of PSA only recurrence of prostate cancer after prior local therapy.
Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels.
Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Trends in diagnosis of stage T1a-b prostate cancer.
Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993.
Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Trends in poorly differentiated prostate cancer 1973 to 1994: observations from the Surveillance, Epidemiology and End Results database.
Trends in prostate cancer epidemiology in the year 2000.
Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines.
Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice.
Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): a Comparison Between the CaPSURE Data and the NUORG Data.
Tumor markers in prostate cancer I: blood-based markers.
Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability.
Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.
Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Tumour markers in patients on deferred treatment: prostate specific antigen doubling times.
Tumour markers in prostatic cancer.
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-?B signalling.
Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer.
Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Undetectable prostate specific antigen in disseminated prostate cancer.
Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen.
Unrealistic optimism and the Health Belief Model.
Unresolving / progressive skin lesions in cancer patients: be aware of carcinoma cutis.
Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.
Update on chemoprevention of prostate cancer.
Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina.
Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy.
Urinary prostate specific antigen: is the clinical use likely?
Urinary PSA in monitoring of patients with prostate cancer.
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL.
Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer.
Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.
Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
Use of mpMRI in active surveillance for localized prostate cancer.
Use of pleural fluid prostate specific antigen in the diagnosis of malignant effusion from metastatic prostate cancer.
Use of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in the diagnosis of prostate cancer--a local experience.
Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.
Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
Use of the prostate specific antigen (P.S.A.) in early detection of prostate cancer in males over the age of 50.
Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
Usefulness of Total PSA Value in Prostate Diseases Diagnosis.
Using molecular markers to predict outcome.
Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection.
Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.
Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.
Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective.
Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in arab men.
Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values.
Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection.
Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.
Validation of a nomogram for predicting positive repeat biopsy for prostate cancer.
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.
Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.
Validation of the partin nomogram for prostate cancer in a national sample.
Validity of digital rectal examination in the era of prostate specific antigen.
Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland.
Value of 18F-Choline PET/MRI hybrid technique on the therapeutic approach for patients with prostate cancer treated with prostatectomy and rising prostate specific antigen levels below 1 ng/ml.
Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters.
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis.
Value of prostate specific antigen in predicting the existence of bone metastasis in scintigraphy.
Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less.
Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients.
Values of prostate specific antigen in patients with operable prostate carcinoma.
Variables in predicting survival based on treating "PSA-only" relapse.
Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening.
Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy.
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis.
Visual electrochemiluminescence ratiometry on bipolar electrode for bioanalysis.
Visual laser ablation of the prostate: clinical experience in 108 patients.
Visual Loss from a Pituitary Mass: Collision Tumors of Prostatic Metastasis and Suprasellar Meningioma.
Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?
Weight Management to Reduce Prostate Cancer Risk: A Survey of Men's Needs and Interests.
What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
When is active surveillance the appropriate treatment for prostate cancer?
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
Why men in the United Kingdom still want the prostate specific antigen test.
Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study.
Willingness to pay for mass screening for prostate cancer: a contingent valuation survey.
Words of wisdom. Re: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
XB130 is overexpressed in prostate cancer and involved in cell growth and invasion.
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.
[11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.
[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.
[A case of primary transitional cell carcinoma of the prostate]
[A Case of Prostate Cancer with High Levels of Prostate-Specific Antigen Undetected by Prostate Biopsy].
[A Case of Rectum-Infiltrating Prostate Cancer Mimicking Prostate-Infiltrating Rectal Cancer].
[A case of solitary endobronchial metastasis of prostatic cancer]
[A low-fat and high soybean protein diet for patients with elevated serum PSA level: alteration of QOL and serum PSA level after the dietary intervention]
[A pilot study of mass screening program for prostatic cancer by means of prostate specific antigen (PSA) filter paper method]
[A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report]
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
[Advancement of treatment for prostate cancer]
[Advances in researches on the relationship between single nucleotide polymorphism and prostate cancer]
[Alternative tests to PSA for prostate cancer diagnosis.]
[An experience of individual and early diagnosis of prostate cancer in a Tunisian centre]
[Analysis of reference range responsible to normal percent value of free prostate specific antigen from men without prostate disease]
[Analysis of the results of percent free prostate specific antigen detection among the men without prostate diseases in Xi'an.]
[Antiandrogen suppression syndrome in patients with hormone-resistant cancer of the prostate]
[Antiandrogen withdrawal syndrome]
[Application of angiotensin II receptor blocker in prostate cancer]
[Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
[Biochemical recurrence criteria after radiotherapy (external beam, brachytherapy). Natural history of the disease after radiotherapy].
[Biological markers of cancer. Critical study]
[Biological markers of prostate cancer]
[Cancer of the prostate stage T1. Incidental carcinoma. Review of the literature and an appraisal of the classification]
[Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers]
[Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy]
[Changes in clinical features of inpatients with prostate cancer in the past 11 years].
[Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer]
[Characteristics of screening-detected prostate cancer on health checkup]
[Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].
[Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer]
[Clinical evaluation of chemiluminescence immunoassay PSA (ACS-PSA) for detection of prostate cancer]
[Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA]
[Clinical profiles of prostate cancer in our hospital: association between primary symptoms and clinical stage]
[Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer]
[Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer]
[Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer]
[Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein]
[Clinical studies on the prognostic factors in prostate cancer]
[Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience]
[Clinical study of prostatic cancer--statistical analysis of 184 cases in the latest 21 years]
[CLINICAL STUDY OF THE PROSTATE CANCERS WITH A SERUM PROSTATE SPECIFIC ANTIGEN LEVEL OF MORE THAN 100 ng/ml AT THE FIRST DIAGNOSIS].
[Clinical study on poor PSA response to initial endocrine therapy with MAB or estrogenic drugs for treatment of prostate cancer]
[Clinical study on prostatic cancer detected incidentally by transurethral resection of the prostate]
[Clinical usefulness of the free and total prostate specific antigen ratio in the diagnosis of cancer of the prostate]
[Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"]
[Clinical value of CK34BE12 combining the expression of protein P53 gene and prostate specific antigen for the differential diagnosis of prostate carcinoma]
[Clinical value of prostate specific antigen screening in early detection of prostate cancer]
[Cloning and expression of androgen response elements of prostate specific antigen promoter]
[Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer]
[Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer]
[Comparison of tumor markers versus their relative values to prostatic volume in detecting prostate cancer]
[Comparison of value of free-to total prostate specific antigen, prostate specific antigen density and prostate specific antigen density of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1-10 ng/ml]
[Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer].
[Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer]
[Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma]
[Current aspects of prostate cancer screening].
[Current status and problems of a screening for prostatic cancer in the health facilities in Fukuoka Prefecture]
[Detection of prostate cancer in urological practice: clinical establishment of serum PSA reference values by age]
[Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy]
[Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
[Diagnosis and follow-up of prostate cancer patients using prostate specific antigen (PSA)]
[Diagnosis and treatment of bladder and prostate cancer in early stages]
[Diagnosis and treatment of early prostate cancer]
[Diagnosis and treatment of localized prostate cancer]
[Diagnosis and treatment of prostatitis: a case report]
[Diagnosis of cancer of the prostate by determining the blood levels of specific prostatic antigen, rectal examination, and transrectal echography]
[Diagnosis Values of Back Propagation Neural Network Integrating Age, Transrectal Ultrasound Characteristics and Serum PSA for Prostate Cancer].
[Diagnostic and prognostic value of quantitative monitoring of prostate specific antigen in blood serum and urine from patients with prostate cancer after radical prostatectomy]
[Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]
[Diagnostic value of tissue and serum prostate specific antigen in prostate cancer]
[Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy]
[Digital rectal examination, transrectal ultrasonography and prostate specific antigen for diagnosis of prostate cancer in clinical urological practice-detection of impalpable cancer]
[Disease relapses after radical radiotherapy of prostate cancer--analysis of prognostic factors]
[Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma]
[Does PSA density of the transition zone represent a useful parameter in the diagnosis of prostate carcinoma?]
[Early detection and follow-up of prostatic carcinoma. Responsibilities of the general practitioner]
[Early diagnosis and surgical management of prostate cancer]
[Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen]
[Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle]
[Effects of digital rectal examination on serum prostate specific antigen]
[Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].
[Enzyme-linked immunosorbent assay for serum prostate specific antigen (PSA) using monoclonal antibodies]
[Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease]
[Epidemiology of prostate cancer in China: an overview and clinical implication].
[Epigenetic markers of early diagnostics of prostate cancer.]
[Etiology of prostate cancer and significance of screening for early prostate cancer]
[Evaluation of prostate specific antigen (PSA) adjusted to transition zone in prostatic cancer detection]
[Evaluation of transrectal power-Doppler ultrasonography and effect of contrast-enhancement for detecting prostate cancer]
[Examination of serum prostate specific antigen (PSA) in the mass screening for prostatic diseases]
[Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group]
[Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer]
[General features and strategy in the diagnosis of prostatic carcinoma]
[Giant subcutaneous hematoma with hemorrhagic shock induced by goserelin acetate injection for prostate cancer : report of a case].
[Histological characteristics and clinical significance of Japanese prostate cancer with low levels of prostate specific antigen of 4.0 ng/ml or lower]
[Histopathological characteristics of radical prostatectomy specimen and long-term PSA changes in men with PSA levels of 4.0 ng/ml or less]
[Hormone replacement Up-to-date. Clinical practice of androgen replacement therapy]
[Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma]
[Influence of age on serum prostate specific antigen concentration]
[Influence of hormonal therapy on the level of prostate specific antigen in patients with advanced prostatic cancer].
[Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study]
[Is it possible to do without bone gammagraphy in the staging of prostatic cancer?]
[Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report].
[Management of High-Risk Prostate Cancer and Left Ectopic Ureter Inserting into Seminal Vesicle with Ipsilateral Hypoplastic Kidney of a Young Patient : A Case Report].
[Mass screening for prostate cancer at Ikeda City in Osaka Prefecture--results of screening with PSA alone between 2003 and 2007]
[Mass screening for prostate cancer in Ikeda City Osaka]
[Mass screening for prostate cancer in Nagano]
[Mass screening for prostate cancer in Tokushima City: the results of 2001]
[Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer]
[Mass screening prostate cancer and clinical comparison]
[Measurement of serum PSA by DELFIA PSA kit and its application for mass screening. The Gunma Urological Oncology Study Group]
[Measurement of serum PSA values by DELFIA PSA and its clinical significance on diagnosis and follow-up of prostate cancer patients]
[Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood]
[Molecular staging of hematogenous microdissemination of prostate cancer cells]
[Multiple myeloma diagnosed during hormonal therapy for prostate cancer: report of two cases].
[Multiple prostatic biopsies in the "gray zone" of the specific prostatic antigen]
[Neuroendocrine differentiation and markers of cell proliferation in a group of patients with prostate adenocarcinoma and normal or high serum prostate-specific antigen levels]
[Non- PSA serum markers for the diagnosis of PCa].
[Non-specific granulomatous prostatitis. Relationship and differential diagnosis with prostatic cancer]
[Occult cancer in patients with symptomatic benign prostatic hyperplasia]
[Opportunity for a systematic screening of prostatic cancer by determining prostate specific antigen levels]
[Pathological features of prostate cancer in Chinese cohort detected through mass screening and their relationships with serum prostate specific antigen]
[Pilot study of screening of prostate cancer by the assay of prostate specific antigen in occupational milieu]
[Preclinical models of prostate cancer]
[Predicting prostate cancers using a logistic regression model with transrectal ultrasound characteristics, age and Serum PSA].
[Prediction of the stage of patients with prostate cancer by the combination of serum prostate specific antigen and Gleason score]
[Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer]
[Prognosis and predictive factors in prostate cancer.]
[Prognostic factors for PSA relapse of prostate cancer after endocrine therapy]
[Prognostic factors of prostatic cancer]
[Pros and cons of active surveillance for low-risk prostate cancer].
[Prostate biopsy]
[Prostate cancer and prostate specific antigen screening]
[Prostate cancer in the elderly patient]
[Prostate cancer screening at Tatebayashi City in Gunma prefecture--results of screening with PSA alone between 2003 and 2005]
[Prostate cancer screening using prostate specific antigen (PSA) in Tokatsu Hospital--examination of lost-to-followup cases]
[Prostate cancer test and medical reimbursement]
[Prostate cancer with an unusual course]
[Prostate cancer. Treatment]
[Prostate cancer: Diagnosis and staging]
[Prostate cancer]
[Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml]
[Prostate specific antigen and diagnosis of prostate cancer]
[Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status]
[Prostate specific antigen in patients with prostatic cancer--clinical usefulness of its measurement with sensitive enzyme immunoassay, TOSOH II PA assay]
[Prostate specific antigen in serum of the patients with prostatic cancer]
[Prostate specific antigen. Clinical applications of ultrasensitive assay]
[Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer]
[Prostate-specific antigen in the follow-up of conservatively treated prostatic cancer]
[Prostate-specific antigen: the most useful marker for prostate cancer]
[Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer]
[Prostatic carcinoma: current status of diagnostic imaging]
[Prostatic carcinoma: immunoperoxidase study with antisera against prostatic acid phosphatase and the prostate-specific antigen]
[PSA doubling time and method of calculation]
[PSA kinetics after radiotherapy]
[PSA kinetics after total prostatectomy]
[PSA level of the transitional zone: a new marker especially reliable for the detection of prostatic cancer]
[PSA-based parameters]
[PSATZ (prostate specific antigen adjusted for the transition zone volume)]
[Purification of prostatic acid phosphatase and prostate specific antigen from human seminal plasma]
[Quadrature coils for magnetic resonance spectroscopy in the detection of prostate cancer: Single voxel acquisition does not improve the diagnostic accuracy of multivoxel images.]
[Questionnaire based evaluation of prostate biopsy complication comparing different bioptic schemes]
[Radiotherapy of localized cancer of the prostate: current status and new strategies]
[Real-time elastography in the diagnosis of prostate cancer: personal experience].
[Recent advances in proPSA on early detection in prostate cancer]
[Related biomarkers in the diagnosis of prostate cancer].
[Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]
[Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy]
[Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer].
[Repeated ultrasound-guided transrectal prostate biopsy in patients with negative histologic test]
[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault]
[Retrospective evaluation of PSA density for selection of biopsy candidates with prostate specific antigen in the gray zone]
[Rising Prostate Specific Antigen following treatment with curative intention]
[Robot-Assisted Laparoscopic Prostatectomy for Patient with Hereditary Hemorrhagic Telangiectasia: A Case Report].
[Role of prostate specific antigen in the early diagnosis of prostatic cancer. New criteria based on its blood determination]
[Role of prostate specific antigen, transrectal ultrasonography, and digital rectal examination in the search for clinical prostate cancer]
[Role of tissue markers on diagnosis, prognosis and monitoring of prostate cancer].
[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients]
[Screening for prostate cancer in Yahata, Kitakyushu]
[Screening for prostate cancer: present status and future perspectives].
[Screening test for prostate cancer]
[Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group]
[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers]
[Serum prostate specific antigen for the early detection of prostate cancer in outpatients of internal medicine]
[Serum prostate-specific antigen in a urological outpatient clinic. Efficacy of age-specific and prostate volume-specific reference range in detection of prostate cancer]
[Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml]
[Significance of PSA-density: analysis in PSA gray zone cases]
[Significance of the PSA-concentration for the detection of prostate cancer]
[Significance of various examination methods in the management of prostatic cancer]
[Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model].
[Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening].
[Staging and therapeutic options in local prostatic carcinoma]
[Status of PSA determination for early detection of prostate carcinoma]
[Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer]
[Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer]
[Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report]
[Summary of 'General Rule for Clinical and Pathological Studies on Prostate Cancer (the 3rd Edition)']
[Surgical therapy of locally confined prostate carcinoma]
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer]
[Systematic prostate biopsy before transurethral resection of the prostate]
[The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer]
[The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer]
[The digital rectal exam, prostate-specific antigen and transrectal echography in the diagnosis of prostatic cancer]
[The Efficacy of Amrubicin Therapy as a Second Line Treatment in Patients with Small Cell Carcinoma of the Prostate : A Case Report].
[The efficacy of PSA density for the early detection of prostate cancer]
[The focus and prospect of prostate cancer research].
[The incidence, mortality and risk factors of prostate cancer].
[The percentage of free prostate specific antigen used in detecting prostate cancer]
[The relationship of PSA to age and prostatic volume in patients with benign prostatic hypertrophy]
[The relationships of PSA, FPSAR, clinical and pathological stage in patients with prostate cancer]
[The result of mass screening of 1997 for prostatic cancer in Isesaki City]
[The role of prostate specific antigen and its derivatives (age-specific PSA, PSA density, velocity, free/total PSA) in the diagnosis of prostate cancer]
[The role of PSA in diagnosis of prostate cancer and its recurrence]
[The significance and limitation of prostate specific antigen in the mass screening for prostate cancer]
[The significance of early detection for prostate cancer in mass screening]
[The survival analysis of the advanced metastatic castration-resistant prostate cancer.]
[The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer]
[The utility of prostate specific antigen doubling time in repeat biopsy for prostate cancer]
[Therapy by endoscopic laser for prostatic obstruction]
[Total PSA, PSA density and biopsy Gleason score in predicting the pathologic stage of prostate cancer]
[Transrectal ultrasound guided biopsies in 266 patients]
[Transrectal ultrasound-guided systematic 12-core biopsy of the prostate improves prostate cancer detection].
[Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy]
[Treatment of metastatic prostate cancer: certainty and doubts]
[Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)]
[Updated treatments of castration-resistant prostate cancer].
[Use of biopsy results to predict capsular perforation and seminal vesicle invasion in prostate cancer]
[Use of prostate specific antigen. A review]
[Use of transrectal ultrasonography in prostate pathology: determination and clinical usefulness of the prostate transition zone]
[Usefulness of free prostate specific antigen in the detection of prostate cancer]
[Usefulness of hyper sensitive PSA assay kits for determination on low range of prostate specific antigen in prostate cancer]
[Usefulness of prostate specific antigen/gamma-seminoprotein ratio for diagnosis of prostate cancer]
[Usefulness of PSA-complex in the diagnosis of prostatic carcinoma]
[Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("human dock") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer]
[Usefulness of ultrasound-guided prostate biopsy in the diagnosis and treatment of localized prostate cancer]
[Utility of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient in detection of prostate cancer and prediction of pathologic Gleason score].
[Utility of prostate specific antigen (PSA) density in detecting prostate cancer in men showing gray zone serum PSA levels]
[Utility of prostate-specific antigen in pleural fluid for the diagnosis of metastatic effusion secondary to prostate cancer]
[Validity of digital rectal examination of prostate specific antigen]
[Value of determining prostate specific antigen in follow-up of prostatic cancer]
[Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)]
[Value of PI-RADS v2 scores combined with prostate specific antigen in diagnosis of peripheral zone prostate cancer: a logistic regression analysis].
[Value of prostate specific antigen in early diagnosis of prostatic cancer]
[Value of prostate volume, PSAD and F/T in the detection of prostate cancer in males with PSA 4-10 ?g/L].
[Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of prostate cancer]
[Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay]
[Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?]
[Yield of ultrasonography-guided transrectal biopsy in the diagnosis of carcinoma of the prostate]
Prostatic Neoplasms, Castration-Resistant
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
Prostatitis
Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.
Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus.
Can expressed prostatic secretions effect prostate biopsy decision of urologist?
Can mean platelet volume serve as a marker for prostatitis?
Case report: laparoscopic ureteropyelostomy and distal ureterectomy for management of duplication with ectopia.
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.
Cranberry intervention in patients with prostate cancer prior to radical prostatectomy. Clinical, pathological and laboratory findings.
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE Study.
Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia.
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Elevation of prostate specific antigen from bacillus Calmette-Guerin-induced granulomatous prostatitis.
Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.
Incidence of histological prostatitis and its correlation with PSA density.
Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value.
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
Primary cryptococcal prostatitis and correlation with serum prostate specific antigen in a renal transplant recipient.
Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.
Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate.
Prostate specific antigen and prostatitis. II. PSA production and release kinetics in vitro.
Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis.
PSA decrease after levofloxacin therapy in patients with histological prostatitis.
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Re: treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia.
Relationship between Serum Prostate Specific Antigen and the Pattern of Inflammation in Both Benign and Malignant Prostatic Disease in Middle Eastern Men.
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis.
Serum prostate specific antigen levels in non-specific granulomatous prostatitis.
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men.
The characterization of nonbacterial prostatitis: search for an etiology.
The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis.
The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.
The fluctuation of PCA3 score in men undergoing first or repeat prostate biopsies.
The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen.
Total and free serum prostate specific antigen levels during the first month of acute prostatitis.
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen.
Treatment of chronic prostatitis lowers serum prostate specific antigen.
[Chronic prostatitis and PSA values.]
[Correlation of histological prostatitis with PSA, prostate volume, PSAD, IPSS, Qmax and PVR in BPH patients].
[Effects of antibiotic and anti-inflammatory treatment on serum PSA and free PSA levels in patients with chronic prostatitis IIIA]
Proteinuria
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Modulation of renal kallikrein by a high potassium diet in rats with intense proteinuria.
Pseudorabies
A trypsin-like serine protease is involved in pseudorabies virus invasion through the basement membrane barrier of porcine nasal respiratory mucosa.
Psoriasis
Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.
Bivalent inhibition of human beta-tryptase.
Puberty, Precocious
Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment.
Pyelonephritis
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Presence of immunoreactive tissue kallikrein in human polymorphonuclear (PMN) leucocytes.
Pyuria
Prostatic Inflammation Detected in Initial Biopsy Specimens and Urinary Pyuria are Predictors of Negative Repeat Prostate Biopsy.
[Granulomatous Prostatitis : Three Cases Report].
Rectal Neoplasms
Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma.
[A Case of Rectum-Infiltrating Prostate Cancer Mimicking Prostate-Infiltrating Rectal Cancer].
Renal Insufficiency
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation.
Effect of magnesium lithospermate B on the renal and urinary kallikrein activities in rats with adenine-induced renal failure.
Laboratory evaluations of erectile dysfunction: an evidence based approach.
Tissue kallikrein and kinins in renal disease.
Renal Insufficiency, Chronic
Prostate specific antigen levels in pre-dialysis chronic kidney disease patients.
Reperfusion Injury
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation.
Human urinary kininogenase reduces the endothelial injury by inhibiting Pyk2/MCU pathway.
Human urine kininogenase attenuates balloon-induced intimal hyperplasia in rabbit carotid artery through transforming growth factor ?1/Smad2/3 signaling pathway.
Therapeutic modulation of tissue kallikrein expression.
Tissue Kallikrein Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the B2R-ERK1/2-CREB-Bcl-2 Signaling Pathway in Diabetic Rats.
Retinal Neovascularization
The kallikrein system in retinal damage/protection.
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Retinal Perforations
Tissue Kallikrein Inhibits Retinal Neovascularization via the Cleavage of Vascular Endothelial Growth Factor 165.
Rhinitis
Localization of immunoreactive tissue kallikrein in the seromucous glands of the human and guinea-pig respiratory tree.
Rhinitis, Allergic
Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis.
Rosacea
Doxycycline Indirectly Inhibits Proteolytic Activation of Tryptic Kallikrein-Related Peptidases and Activation of Cathelicidin.
Endoplasmic reticulum stress: key promoter of rosacea pathogenesis.
Kallikrein 5-Mediated Inflammation in Rosacea: Clinically Relevant Correlations with Acute and Chronic Manifestations in Rosacea and How Individual Treatments May Provide Therapeutic Benefit.
Sarcoidosis
Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography.
Sarcoma, Avian
Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats.
Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats.
Schistosomiasis
[Prothrombin and prokallikrein in a patient with hepatosplenic schistosomiasis: effects of heparinization and splenectomy]
Scleroderma, Systemic
Differential expression of tissue kallikrein in the skin of systemic sclerosis.
Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement.
The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis.
Seminoma
New cancer markers.
Sepsis
Association between pre-biopsy white blood cell count and prostate biopsy - related sepsis.
Granzyme K activates protease-activated receptor-1.
Tissue Kallikrein Exacerbating Sepsis-Induced Endothelial Hyperpermeability is Highly Predictive of Severity and Mortality in Sepsis.
Sexually Transmitted Diseases
Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration.
Shock, Cardiogenic
Acute myocardial infarction without cardiogenic shock does not affect serum prostate specific antigen levels: A case control study.
Shock, Septic
A near-fatal case of sepsis with an antibiotic-resistant organism complicating a routine transrectal prostate biopsy in a health care worker.
Sialadenitis
Effect of radioactive iodine therapy on parotid gland function.
Situs Inversus
Incidental Finding of Dextrocardia with Situs Inversus in a 59-Year-Old Man.
Sjogren's Syndrome
Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren's syndrome.
Skin Diseases
Expression and ultrastructural localization of plasmin(ogen) in the terminally differentiated layers of normal human epidermis.
Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases.
Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
Skin Neoplasms
Screening for cancer. Is it useful?
Sleep Apnea, Obstructive
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Sleep Initiation and Maintenance Disorders
A top 5 list for French general practice.
Spinal Cord Injuries
Evaluation of serum and seminal levels of prostate specific antigen in men with spinal cord injury.
Seminal plasma PSA in spinal cord injured men: a preliminary report.
Spinal Diseases
Anorectal application of 5% lidocaine cream reduces pain prior to periprostatic nerve block during transrectal ultrasound guided prostate biopsy: Randomized, prospective controlled study.
Squamous Cell Carcinoma of Head and Neck
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
Starvation
Exocrine and endocrine release of kallikrein after reflex-induced salivary secretion.
Stomach Neoplasms
Associations of race, education, and patterns of preventive service use with stage of cancer at time of diagnosis.
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer.
Stomach Ulcer
Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms.
The evaluation of tissue kallikrein in Helicobacter pylori-associated gastric ulcer disease.
[Bio- and histochemical changes of tissue kallikrein in the rat stomach after water immersion-induced gastric ulcer]
[Correlation between glandular kallikrein and experimental gastric ulcer in rats]
Stroke
Effects of Urinary Kallidinogenase on NIHSS score, mRS score, and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism: A prospective cohort study.
Efficacy and safety of human urinary kallidinogenase for acute ischemic stroke: a meta-analysis.
Human Urinary Kallidinogenase decreases recurrence risk and promotes good recovery.
Human Urinary Kallidinogenase Improves Outcome of Stroke Patients by Shortening Mean Transit Time of Perfusion Magnetic Resonance Imaging.
Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke.
Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB.
Increase in Blood-Brain Barrier Permeability is Modulated by Tissue Kallikrein via Activation of Bradykinin B1 and B2 Receptor-Mediated Signaling.
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Plasma tissue kallikrein level is negatively associated with incident and recurrent stroke: A multicenter case-control study in China.
The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat.
Tissue Kallikrein Activity, Detected by a Novel Method, May Be a Predictor of Recurrent Stroke: A Case-Control Study.
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
Subarachnoid Hemorrhage
Human tissue kallikrein ameliorates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
Tissue kallikrein: A potential serum biomarker to predict delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage.
[Effects of human tissue kallikrein on cerebral vasospasm: experiment with rabbits]
[Effects of human urinary tissue kallikreins on vasodilation of basilar artery in rabbits with symptomatic cerebral vasospasm]
Synovitis
A tissue kallikrein in the synovial fluid of patients with rheumatoid arthritis.
Teratoma
Concurrent primary carcinoid tumor arising within mature teratoma and clear cell renal cell carcinoma in the horseshoe kidney: report of a rare case and review of the literature.
Testicular Neoplasms
Embryonal carcinoma of the testis associated with prostate cancer in a 72-year-old man.
Thromboangiitis Obliterans
Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans.
Thrombocytopenia
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Thromboembolism
Recent progress in hormonal therapy for advanced prostate cancer.
Thrombosis
Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin.
High-Throughput Docking and Molecular Dynamics Simulations towards the Identification of Potential Inhibitors against Human Coagulation Factor XIIa.
Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants.
The factor VII zymogen structure reveals reregistration of beta strands during activation.
Thymoma
Imaging Comparison between (18) F-FDG-PET/CT and (18) F-Flouroethyl Choline PET/CT in Rare Case of Thymus Carcinoma Exhibiting a Positive Choline Uptake.
tissue kallikrein deficiency
Kallikrein protects against microalbuminuria in experimental type I diabetes.
Partial genetic deficiency in tissue kallikrein impairs adaptation to high potassium intake in humans.
Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice.
Tissue kallikrein deficiency and renovascular hypertension in the mouse.
Tissue kallikrein deficiency, insulin resistance and diabetes in mouse and man.
Tuberculosis
Pauci-symptomatic disseminated tuberculosis revealed by an increase in the specific antigen of the prostate.
Ureteral Calculi
Effect of extracorporeal shock wave lithotripsy on prostate specific antigen.
Extracorporeal shockwave lithotripsy in patients with distal ureteral calculi does not influence the prostate specific antigen value.
Ureteral Obstruction
Differential effects of ureteral obstruction on rat kininogen gene family.
The kininogen gene family in obstructive uropathy.
Urethral Obstruction
Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.
Urethral Stricture
Rating general practitioner consultation performance in cancer care: does the specialty of assessors matter? A simulated patient study.
Urinary Bladder Calculi
Patient selection and counseling before prostatic arterial embolization.
Urinary Bladder Diseases
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Urinary Bladder Neck Obstruction
2-year followup pressure flow studies of prostate photoselective vaporization using local anesthesia with sedation.
Assessment of noninvasive predictors of bladder outlet obstruction and acute urinary retention secondary to benign prostatic enlargement.
Routine estimation of prostate specific antigen prior to clinic attendance in patients with symptoms of bladder outlet obstruction.
Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms.
The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients.
[Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia]
Urinary Bladder Neoplasms
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System.
Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Current bladder tumor tests: does their projected utility fulfill clinical necessity?
Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival.
Potency preserving cystectomy with intrafascial prostatectomy for high risk superficial bladder cancer.
Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen.
Total or partial prostate sparing cystectomy for invasive bladder cancer: long-term implications on erectile function.
Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder.
Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model.
Urinary Bladder, Neurogenic
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Urinary Bladder, Overactive
Deficits in urological knowledge among medical students and primary care providers: potential for impact on urological care.
Efficacy of Adding Dutasteride to ?-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30?mL).
Urological knowledge among primary health care physicians in Saudi Arabia.
Urinary Incontinence
Quality control of radical prostatectomy: a feasibility study.
Urinary Retention
Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Assessment of noninvasive predictors of bladder outlet obstruction and acute urinary retention secondary to benign prostatic enlargement.
Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Giant prostatic hyperplasia and its causes.
Holmium laser enucleation of the prostate--outcomes independent of prostate size?
Holmium Laser Enucleation vs Bipolar Plasmakinetic Enucleation of a Large Volume Benign Prostatic Hyperplasia: A Randomized Controlled Trial.
Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass.
Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Simple perineal prostatectomy: lessons learned from a modern series.
Simultaneous transurethral resection of prostate and prostate needle biopsy in patients with acute urinary retention and elevated prostate specific antigen levels.
Urinary retention and post-void residual urine in men: separating truth from tradition.
Validity of PSA, free/total PSA ratio and complexed/total PSA ratio measurements in men with acute urinary retention.
[Serum PSA and transition zone index as predictors of acute urinary retention in benign prostate hyperplasia]
[The effect of acute urinary retention on serum prostate specific antigen concentration]
[Value of PSA/gamma-Sm ratio (P/S ratio) for diagnosis of prostate cancer in patients with urinary retention]
Urinary Tract Infections
Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen.
Patient selection and counseling before prostatic arterial embolization.
Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.
Prostate specific antigen in urinary tract infection.
Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis.
Urologic Diseases
[Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein]
[Prostate-specific antigen. Interpretation of the results in relation to the sampling method]
[Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay]
Uterine Cervical Neoplasms
Angiogenesis in cervical cancer is mediated by HeLa metabolites through endothelial cell tissue kallikrein.
Ethical issues for cancer screening.
Ethical issues for cancer screenings. Five countries--four types of cancer.
Vaccinia
A Phase I Trial of Pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMtrade mark) in Patients with Prostate Cancer.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Vascular Ring
Proteinase-activated receptors, targets for kallikrein signaling.
Vascular System Injuries
Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity.
Vasospasm, Intracranial
Human tissue kallikrein ameliorates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
[Effects of human tissue kallikrein on cerebral vasospasm: experiment with rabbits]
[Effects of human urinary tissue kallikreins on vasodilation of basilar artery in rabbits with symptomatic cerebral vasospasm]
Ventricular Dysfunction, Left
Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene.
Vesico-Ureteral Reflux
Significance of the tissue kallikrein promoter and transforming growth factor-beta1 polymorphisms with renal progression in children with vesicoureteral reflux.
Virus Diseases
Tissue kallikrein regulates alveolar macrophage apoptosis early in influenza virus infection.
Wilms Tumor
Adenocarcinoma of the rete testis with prominent papillary structure and clear neoplastic cells: morphologic and immunohistochemical findings and differential diagnosis.